Ministry of Chemicals and Fertilizers

Period of Analysis: 08/10/2026 to 09/10/2026

पत्र सूचना कार्यालय
PRESS INFORMATION BUREAU
भारत सरकार

Dossier Name: Media Coverage report of TMR

Dossier Created On: 09/10/2026

सत्यमेव जयते

रसायन एवं
उर्वरक मंत्रालय
MINISTRY OF
CHEMICALS
AND FERTILIZERS

PRINT MEDIA

Downloaded from
SAMVAD 2.0

Report Summary

Publication: 27	Edition: 13	Sentiment: POSITIVE (100%)
Languages: Telugu, Marathi, Tamil, Hindi, Malayalam, English		

Title: Government Regulatory Actions to Enhance Pharmaceutical Affordability and Ethical Standards

Summary: The Indian government has initiated a significant policy shift to improve the affordability of life-saving cancer treatments by imposing a 30 percent cap on trade margins for non-scheduled anti-cancer drugs. This regulatory measure, managed by the Department of Pharmaceuticals, the National Pharmaceutical Pricing Authority, and the Directorate General of Health Services, is set to impact approximately 110 drugs, potentially lowering retail prices by as much as 70 percent. The initiative is expected to generate annual savings of up to 2,500 crore rupees for patients nationwide. This intervention follows strong criticism from the Supreme Court, which characterized current pharmaceutical pricing practices as excessive profiteering. Beyond price controls, the Supreme Court has mandated the formation of a government committee to address unethical marketing practices, specifically targeting the influence of pharmaceutical companies on healthcare professionals through gifts and other inducements. As the government finalizes the list of affected domestic and imported medications, these measures represent a comprehensive effort to balance market accountability with the essential need for accessible healthcare.

Downloaded from
SAMVAD 2.0

Sr. No.	Headline	Publication	Edition	Page No.	Sentiment	Date
1	Govt to cap cancer drug trade margins	The Times of India	Jaipur	1,6	POSITIVE	09/10/2026
2	GOVT DECIDES TO CAP MARGINS ON CANCER DRUGS AT 30% OF MRP	The Hindustan Times	Delhi	9	POSITIVE	09/10/2026
3	Govt to put 30% cap on trade margin of 110 non-scheduled cancer drugs	The Indian Express	Delhi	1,2	POSITIVE	09/10/2026
4	Govt. to cap trade margins at 30% of MRP for cancer drugs	The Hindu	Delhi	14	POSITIVE	09/10/2026
5	Cancer drugs all set to become cheaper	The New Indian Express	Bengaluru	1,11	POSITIVE	09/10/2026
6	PANEL REPORT BY OCT 14: Several Anti-cancer Drugs may Get up to 70% Cheaper	The Economic Times	Delhi	1,10	POSITIVE	09/10/2026
7	PANEL REPORT BY OCT 14 Govt to Name Anti-cancer Drugs for 30% Margin Cap	The Economic Times	Kolkata	1,13	Positive	09/10/2026
8	Centre to cap trade margin at 30% for anti-cancer drugs	The Tribune	Himachal	1,11	Positive	09/10/2026
9	Cancer drug prices likely to fall as govt caps trade margins at 30% of MRP	The Hindu Business Line	Delhi	12	POSITIVE	09/10/2026
10	Cancer drug prices likely to fall as govt caps trade margins at 30% of MRP	The Hindu Business Line	Hyderabad	12	POSITIVE	09/10/2026
11	Govt to cap trade margins on non-scheduled cancer drugs	Business Standard	Delhi	13	POSITIVE	09/10/2026
12	Prices of 110 anti-cancer drugs to fall	Financial Express	Delhi	1,6	Positive	09/10/2026
13	Centre plans 30% margin cap on key cancer medicines	Mint	Delhi	2	POSITIVE	09/10/2026
14	30 percent profit margin to be fixed on 68 cancer drugs	Hindustan	Bareilly	17	POSITIVE	09/10/2026
15	SC strict to stop 'freebies' of pharma companies	Navbharat Times	Faridabad	3	POSITIVE	09/10/2026
16	Supreme Court to curb unethical marketing practices of pharma companies: Maximum 30% margin fixed on 110 cancer drugs	Dainik Jagran	Siliguri	13	POSITIVE	09/10/2026
17	Central government in action after Supreme Court's query: 110 cancer drugs to become up to 70% cheaper, trade margin to be capped at 30%	Dainik Bhaskar	Indore	1	POSITIVE	09/10/2026
18	Cancer drugs to be up to 70% cheaper; trade margin capped at 30%	Amar Ujala	Delhi	1,18	POSITIVE	09/10/2026

Downloaded from
SAMVAD 2.0

Sr. No.	Headline	Publication	Edition	Page No.	Sentiment	Date
19	Shooter Parminder Kaka arrested in 'Mad Sandhu' murder case; Sellers will not be able to charge more than 30% profit on cancer drugs!	Punjab Kesari	Chandigarh	1	POSITIVE	09/10/2026
20	Impact of Supreme Court's remark: MRP could be reduced by up to 70 percent. 'Robbery' of profits in cancer drugs will stop, margin will be capped at 30 percent.	Rajasthan Patrika	Chennai	12	POSITIVE	09/10/2026
21	Scissors on Cancer Drug Prices! 30 Percent Limit on Trade Margin: Centre.. Implementation from the end of this month	Andhra Jyothi	Visakhapatnam	2	POSITIVE	09/10/2026
22	Cancer drug prices reduced; 30 percent cap set for retail sale; Central Government action	Daily Thanthi	Bengaluru	1	POSITIVE	09/10/2026
23	Govt caps trade margins on anti-cancer drugs at 30%; SC calls for committee on unethical pharma practices	Deccan Chronicle	Chennai	4	POSITIVE	09/10/2026
24	SC asks panel to check pharma advt violations; PERMANENT LIFELINE FOR SMA CARE; CANCER DRUG PRICES LIKELY TO FALL 70%	Deccan Chronicle	Visakhapatnam	5	POSITIVE	09/10/2026
25	CANCER DRUG PRICES CAPPED: GOVT SETS 30% TRADE MARGIN	First India	Jaipur	5	POSITIVE	09/10/2026
26	Cancer medicines to become up to 70% cheaper	Lokmat	Delhi	1	POSITIVE	09/10/2026
27	Trade margin of cancer drugs reduced	Malayala Manorama	Delhi	7	POSITIVE	09/10/2026
28	Prices of 225 cancer drugs will decrease	Navodaya Times	Delhi	1	POSITIVE	09/10/2026
29	Expensive cancer drugs could become up to 70 percent cheaper	Rashtriya Sagar	Delhi	1	POSITIVE	09/10/2026
30	GOVT CAPS TRADE MARGINS AT 30% CANCER DRUGS PRICES LIKELY TO FALL BY 70%	The Hans India	Hyderabad	7	POSITIVE	09/10/2026

Publication Name: The Times of India
Publication Date: 09/10/2026
Language: English
Edition: Jaipur
Page No: 1
CCM: 19.85

Govt to cap cancer drug trade margins

In a move that could reduce patient bills, govt has decided to cap trade margins for all cancer drugs at 30% of MRP. The move could slash MRPs of the drugs by 20-70%, officials told TOI. P6

Related News:

Publication Name: The Times of India

Publication Date: 09/10/2026

Language: English

Edition: Jaipur

Page No: 6

CCM: 135.83

Cancer drug prices may fall as govt plans 30% trade margin cap

Rupali.Mukherjee
@timesofindia.com



New Delhi: In a move that could substantially reduce patient bills, govt has decided to cap trade margins at 30% of MRP for all cancer drugs, covering essential, non-scheduled, branded and generic medicines, as well as domestic and patented drugs.

This could slash MRPs of life-saving cancer drugs by 20-70%, and result in annual savings of Rs 2,500 crore, while improving affordability and ensuring their continued availability, officials told **TOI**.

The move seeks to address "excessive trade mark-ups" in the anti-cancer medicines market that is valued around Rs 12,500 crore, and covering approximately 225 drugs and 500 formulations. Of this, scheduled cancer drugs account for approximately Rs 2,250 crore, with the rest comprising non-scheduled drugs.

The trade margin rationalisation is being done through para 19 of the Drugs Prices Control Order, (DPCO) 2013 that allows govt to fix ceiling or retail price of any drug, or cap trade margins in extraordinary circumstances, and under public interest.

MRP of certain life-saving cancer medicines can run into several lakhs for a single dose, adding significantly to patients' financial burden. An analysis by NPPA indicates that non-scheduled anti-cancer drugs carry an average trade mark-up of approx 170%, with mark-ups of up to 700% in certain cases.

Summary:

The Indian government, through the National Pharmaceutical Pricing Authority (NPPA), has decided to cap trade margins for all cancer drugs at 30% of the Maximum Retail Price (MRP). This initiative aims to address excessive mark-ups in the Rs 12,500 crore anti-cancer medicine market, providing significant financial relief to patients nationwide by reducing drug prices by 20-70%.

Publication Name: The Hindustan Times
Publication Date: 09/10/2026
Language: English
Edition: Delhi
Page No: 9
CCM: 130.21

GOVT DECIDES TO CAP MARGINS ON CANCER DRUGS AT 30% OF MRP

Press Trust of India
letters@hindustantimes.com

NEW DELHI: The Centre has decided to cap trade margins at 30% of the MRP for all non-scheduled anti-cancer drugs, a move which is expected to reduce their maximum retail price by up to 70%, an official statement said on Thursday.

The move will lead to an estimated annual savings of ₹ 2,500 crore for cancer patients, it said.

The non-scheduled anti-cancer drugs will cover branded and generic, domestic and imported, patented and non-patented medicines, according to insiders.

In a notification, the National Pharmaceutical Pricing Authority (NPPA), the regulatory body that controls prices of pharmaceutical drugs, noted that the intervention may reduce MRP broadly in the range of 20-70%, depending upon the existing trade structure and mark-up of individual medicines.

Cancer incidence is rising in India, with approximately 60 people per 100,000 population affected by cancer, the statement said, adding that the treatment places a heavy financial burden on patients and their families, who often have to pay substantial amounts from their own pockets. "NPPA's analysis of market data found that non-scheduled anti-cancer medicines carry an average price mark-up of approximately 170 per cent, reaching 700 per cent or more in some cases. In simple terms," the official statement said.

The decision, expected to be implemented later this month, will bring down prices of 110 anti-cancer drugs, including 35 patented medicines.

"The primary aim of the trade margin rationalisation (TMR) is to prevent mis-selling malpractices. There is a tendency to sell drugs having a bigger margin, and since anti-cancer drugs are more expensive than the rest, we wanted to cap the trade margins on them," the insiders said.

The NPPA said in a meeting held on Thursday, it approved, in principle, the proposal for trade margin rationalisation of identified non-scheduled anti-cancer drugs. The Supreme Court, on September 29, voiced its concern on the issue of highly inflated prices of anti-cancer drugs.

Summary:

• The Indian government, through the National Pharmaceutical Pricing Authority (NPPA), has capped trade margins on non-scheduled anti-cancer drugs at 30% of MRP.
• This initiative aims to reduce drug prices by up to 70%, saving patients ₹2,500 crore annually.
• The decision follows Supreme Court concerns regarding the high cost of cancer treatment in India.

Publication Name: The Indian Express
Publication Date: 09/10/2026
Language: English
Edition: Delhi
Page No: 1
CCM: 73.06

Govt to put 30% cap on trade margin of 110 non-scheduled cancer drugs

Anonna Dutt
New Delhi, October 8

IN A move to address excessive markups on cancer drug prices, the Centre has decided to cap the trade margin at 30 per cent for 110 non-scheduled cancer drugs, including 35 patented medicines. While the list is still being finalised, it will cover branded and generic, domestic and imported, patented and non-patented medicines.

Trade margin is the difference between the price at which a distributor procures a drug from a pharmaceutical manufacturer, and the final Maximum Retail Price (MRP) paid by the patient.

Sources in the Department of Pharmaceuticals said the move, which is likely to come into effect in about 10 days, is expected to see a fall in prices by up to 70 per cent in some cases.

Officials said an analysis of market data by the National Pharmaceutical Pricing

»CONTINUED ON PAGE 2

Related News:

Publication Name: The Indian Express

Publication Date: 09/10/2026

Language: English

Edition: Delhi

Page No: 2

CCM: 118.11

Cancer medicines

Authority had found that the average trade mark-up for such drugs was approximately 170 per cent, extending up to 700 per cent in some cases. The analysis noted significant differences between the prices at retail outlets, hospitals and online pharmacies.

Last month, the Supreme Court, too, had expressed concern over the steep markup on medicines by hospitals, saying that it was "broad daylight dacoity". "This is carnage. Plain and simple. The cancer drug is priced at an MRP of Rs 27,000 despite being supplied to retailers for Rs 2,700," the court had said. "Why not keep a 16 per cent margin on MRP of everything," it had said.

Sources said the list of 110 non-scheduled cancer drugs is being finalised by a committee under the Director General of Health Services. The prices of scheduled drugs, which are part of the National List of Essential Medicines, are already controlled by the government under its Drugs (Prices Control) Order 2013.

"One of the considerations for selecting a medicine (for capping trade margin) is that it should be expensive. This is because a 30 per cent cap on trade margin for cheaper drugs can disincentivise companies as it would not cover the marketing costs. Other than that, the drug, of course, should be approved for treatment of cancer in India and used frequently," said an official from the Department of Pharmaceuticals.

In 2019, the National Pharmaceutical Pricing Authority had capped trade margins for 42 cancer medicines at 30 per cent. This was found to have resulted in MRP reductions by up to 91%.

Summary:

The Department of Pharmaceuticals, following Supreme Court criticism of high trade mark-ups as "broad daylight dacoity," is capping trade margins at 30% for 110 non-scheduled cancer drugs. This initiative, reported by Anonna Dutt in New Delhi, involves the Director General of Health Services and the National Pharmaceutical Pricing Authority to reduce MRPs and patient costs by up to 70%.

Publication Name: The Hindu
Publication Date: 09/10/2026
Language: English
Edition: Delhi
Page No: 14
CCM: 108.33



Govt. to cap trade margins at 30% of MRP for cancer drugs

In a bid to make cancer treatment more affordable and reduce patients' out-of-pocket expenditure, the Union government has decided to cap trade margins at 30% of the maximum retail price (MRP) for all non-scheduled anti-cancer drugs. The measure will cover branded and generic drugs, domestically manufactured and imported medicines, and patented and non-patented products. An expert committee under the Directorate General of Health Services (DGHS) will finalise the list of medicines to be brought under the measure. The National Pharmaceutical Pricing Authority (NPPA), found that the average trade mark-up on non-scheduled anti-cancer medicines was around 170%, with mark-ups reaching up to 700% in some cases.

Summary:

The Union government, through the National Pharmaceutical Pricing Authority (NPPA) and Directorate General of Health Services (DGHS), has capped trade margins for non-scheduled anti-cancer drugs at 30% of MRP. This initiative aims to make cancer treatment more affordable by curbing excessive mark-ups, which previously reached up to 700% in some cases.

Publication Name: The New Indian Express
Publication Date: 09/10/2026
Language: English
Edition: Bengaluru
Page No: 1
CCM: 25.42

EXPRESS READ

Cancer drugs all set to become cheaper

New Delhi: Cancer drugs will soon will see a 70% drop in retail prices as the Centre is set to cap trade margins at 30% over the cost to distributors. This will bring down prices of 110 anti-cancer drugs | **P11**

Related News:

Publication Name: The New Indian Express

Publication Date: 09/10/2026

Language: English

Edition: Bengaluru

Page No: 11

CCM: 330.27

Cancer drugs all set to become cheaper

KAVITA BAJELI-DATT @ New Delhi

CANCER drugs will soon become cheaper as the Centre is all set to announce capping trade margins at 30% over the cost to distributors.

According to official sources, the move will mean that cancer drugs will see a 70% slash in retail prices. This will help bring down prices of 110 anti-cancer drugs, including 35 patented medicines, sources added.

The Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilizers, which will be announcing the price cut in cancer drugs in ten days, comes in the wake of the Supreme Court questioning the huge gap between the Price to Retailer (PTR) and Maximum Retail Price (MRP) of some cancer medicines.

Official sources said the government plans to cap trade margins at 30 % of maximum retail price for all non-scheduled anti-cancer drugs, covering branded and generic, domestic and imported, patented, and non-patented medicines.

The decision would address excessive trade mark-ups and aims to improve affordability while ensuring continued availability of these life-saving medicines. The step will lead to an estimated annual savings of ₹2,500 crore for cancer patients, official sources added.



On September 29, the apex court had voiced its concern on the issue of the highly inflated price of anti-cancer drugs.

Batting for a uniform 16 % margin on all medicines, a bench of Justice Vikram Nath and Justice Sandeep Mehta told Solicitor General Tushar Mehta, appearing for the centre, "This is carnage. Plain and simple. The cancer drug is priced at an MRP of ₹27,000 despite being supplied to retailers for ₹2,700."

The apex court had also questioned why a common uniform margin was not considered for medicines and asked the government to examine the issue.

SC directs Centre to form committee to check unethical pharma freebies to doctors

SUCHITRA KALYAN MOHANTY @ New Delhi

THE SC on Thursday told the Centre to constitute a committee to review representations on unethical drug promotion practices and implementation of the marketing code for pharmaceutical companies offering freebies to doctors.

A two-judge Bench headed by Justice Vikram Nath and comprising Justice Sandeep Mehta passed the order while hearing a PIL filed by the Federation of Medical & Sales Representatives Associations of India (FMSRAI) and others. The committee will submit its recommendations to the Centre. The matter has been listed for January 29 for consideration of UOI's compliance affidavit.

The petition sought statutory regulation of unethical marketing practices by pharmaceutical companies, challenging the voluntary regulatory regime. The petitioners argued that pharmaceutical companies continue to spend on promotion to influence doctors, resulting in prescriptions, sales and over-prescription, which they said infringes citizens' right to life and health.

The SC reserved its verdict on September 8, 2026. The National Medical Commission had kept in abeyance its 2023 conduct regulations restricting doctors from prescribing branded medicines.

Code prohibits gifts to medics, court told

The Centre told the court that the Uniform Code for Pharmaceutical Marketing Practices prohibits companies from offering gifts, travel facilities, hospitality, cash or monetary grants to doctors or families.

Summary:

The Indian Central Government is set to cap trade margins on 110 anti-cancer drugs at 30% over distributor costs, a move expected to reduce retail prices by 70% and save patients ¹2,500 crore annually. Simultaneously, the Supreme Court, led by Justices Vikram Nath and Sandeep Mehta, has directed the Centre to form a committee to curb unethical pharmaceutical marketing practices following a PIL filed by the FMSRAI.

Publication Name: The Economic Times
Publication Date: 09/10/2026
Language: English
Edition: Delhi
Page No: 1
CCM: 1026.47

PANEL REPORT BY OCT 14

Several Anti-cancer Drugs may Get up to 70% Cheaper

The government will cap trade margins on non-scheduled anti-cancer drugs at 30%, resulting in up to 70% price cuts on several medicines. An expert panel will draw up a list of drugs under this. **Teena Thacker** reports. ▶▶ 6

Related News:

Publication Name: The Economic Times

Publication Date: 09/10/2026

Language: English

Edition: Delhi

Page No: 10

CCM: 342.04

GOVT FIXES TRADE MARGINS ON NON-SCHEDULED MEDICINES AT 30%

Cancer Drugs May Get up to 70% Cheaper


Teena Thacker

New Delhi: The government has decided to cap trade margins on non-scheduled anti-cancer drugs at 30%, a move that could reduce the prices of several cancer medicines by up to 70% and save patients an estimated ₹2,500 crore annually, officials told **ET**.

Following this, the department of pharmaceuticals asked the health ministry to constitute an expert committee to recommend the list of the medicines to be covered under the trade margin rationalisation (TMR) exercise.

The committee under the directorate general of health services (DGHS) is expected to submit its list by October 14, according to the minutes of a recent meeting at the National Pharmaceutical Pricing Authority (NPPA). "The positive list may be updated periodically based on market developments and public health considerations," the minutes showed.

The cap will apply to branded and generic drugs, domestic and imported products, and patented as well as non-patented medicines, officials ET spoke with said.



As part of the measure, manufacturers of the covered medicines will be required to maintain their current production levels to ensure that supplies of these life-saving drugs are not disrupted. Since the move only regulates the trade margin, manufacturers' selling prices and revenues will not be affected, the officials explained.

To be sure, the MRP is set by the manufacturer or marketing company. They are expected to bring it down as the new rule limits the share that can accrue to the trade. The 30% cap translates into a trade margin of 42.86% on the price to the stockist.

The government decision comes days after the Supreme Court raised concerns over the pricing of cancer medicines and questioned the Centre over a drug reportedly supplied to retailers for around ₹2,700 but sold at MRP of ₹27,000.

EXTRAORDINARY CIRCUMSTANCES

The minutes of the NPPA meeting said the authority "deliberated upon the need to address excessive trade markups in non-scheduled anti-cancer medicines" and observed that "extraordinary circumstances warrant intervention under Paragraph 19 of DPCO, 2013 in public interest".

Paragraph 19 of the order empowers the government to fix the ceiling or retail price of a drug in extraordinary circumstances and in public interest. The authority observed that "extraordinary circumstances existed" to address market distortions, curb profiteering and ensure fair and affordable prices.

An NPPA analysis found that non-scheduled anti-cancer medicines carry an average trade markup of around 170%, with the margin on some drugs going up to 700%. The minutes also noted substantial variations in transaction prices across retail, hospital and e-pharmacy channels, including significant differences in discounts from MRP.

"The authority accordingly noted that high trade margins, particularly in non-scheduled anti-cancer formulations, are a significant factor contributing to the high prices of such medicines," according to the minutes.

The NPPA expects the proposed intervention to reduce the MRP by broadly 20-70%, depending on the existing trade structure and markup of individual medicines, and estimates annual savings of around ₹2,500 crore.

The authority said the move would help reduce patients' out-of-pocket expenditure, improve affordability and accessibility, curb excessive trade markups and increase transparency in prices applicable to patients. Officials said patients bear nearly 75% of cancer treatment costs out of pocket.

The Working Group on Access to Medicines and Treatments (WGAMT), a civil society networking working for affordable healthcare in India, however, said the 30% trade margin cap would not make non-scheduled cancer medicines affordable, arguing that such a capping in 2019 didn't help much.

For instance, the margin on ribociclib was capped at 30% in 2019, but its monthly cost rose from ₹58,000 in 2022 to ₹78,000 in 2025, WGAMT co-convenors Jyotsna Singh and KM Gopakumar said. Pembrolizumab (Keytruda) still costs around ₹1,95,000 per vial, they added.

Summary:

The Indian government, through the National Pharmaceutical Pricing Authority (NPPA), has capped trade margins on non-scheduled anti-cancer drugs at 30%, a move expected to reduce prices by up to 70% and save patients ¹2,500 crore annually. While journalist Teena Thacker reports that an expert panel will finalize the list of affected medicines by October 14 to improve affordability following Supreme Court concerns, WGAMT co-convenors Jyotsna Singh and KM Gopakumar remain skeptical about the measure's overall effectiveness.

Publication Name: The Economic Times
Publication Date: 09/10/2026
Language: English
Edition: Kolkata
Page No: 1
CCM: 32.65

PANEL REPORT BY OCT 14

Govt to Name Anti-cancer Drugs for 30% Margin Cap

The Centre is preparing to identify the anti-cancer medicines that will come under a proposed 30% trade-margin cap, with an expert committee under the DGHS expected to submit its report by October 14. ▶▶ 11

Related News:

Publication Name: The Economic Times

Publication Date: 09/10/2026

Language: English

Edition: Kolkata

Page No: 13

CCM: 115.28

Govt Caps Margins at 30% for Non-Scheduled Cancer Drugs

New Delhi: The government has decided to cap trade margins on all non-scheduled anti-cancer drugs at 30% of the maximum retail price (MRP), a move that could reduce the prices of several cancer medicines by up to 70% and save patients an estimated ₹2,500 crore annually, officials told **ET**. The cap will apply to branded and generic drugs, domestic and imported products, and patented as well as non-patented medicines, they said.

The move comes days after the Supreme Court raised concerns over the pricing of cancer medicines and questioned the Centre over a drug reportedly supplied to retailers for around ₹2,700 but sold at an MRP of ₹27,000.

An analysis by the National Pharmaceutical Pricing Authority (NPPA) recently found that non-scheduled anti-cancer drugs carry an average trade mark-up of around 170%, with the mark-up rising to as much as 700% in some cases. The analysis also found significant differences in prices across retail pharmacies, hospitals and online pharmacies.

Anti-cancer drug mkt has around 225 drugs and 500 formulations, with annual turnover of ₹12,500 cr

Drugs covered under the margin cap will be identified through a list to be finalised by an expert committee under the Directorate General of Health Services (DGHS), officials cited above said. As part of the measure, manufacturers of the covered medicines will be required to maintain their current production levels to ensure that supplies of these life-saving drugs are not disrupted. Since the move only regulates the trade margin, manufacturers' selling prices and revenues will not be affected, the officials explained. —**Our Bureau**

Summary:

The Central Government, through an expert committee under the Directorate General of Health Services (DGHS) and the National Pharmaceutical Pricing Authority (NPPA), has capped trade margins on non-scheduled anti-cancer drugs at 30%. This initiative, prompted by Supreme Court concerns over exorbitant pricing, aims to make cancer treatment significantly more affordable by reducing patient costs by up to 70% across India.

Publication Name: The Tribune
Publication Date: 09/10/2026
Language: English
Edition: Himachal
Page No: 1
CCM: 45.78

Centre to cap trade margin at 30% for anti-cancer drugs

AKSHEEV THAKUR
TRIBUNE NEWS SERVICE

NEW DELHI, OCTOBER 8

The Centre has decided to cap trade margins at 30 per cent of the MRP for all non-scheduled anti-cancer drugs, covering branded and generic, domestic and imported, patented and non-patented medicines, to reduce the financial burden on patients.

The decision, which is expected to be implemented later this month, will bring

CONTINUED ON PAGE 9

Related News:

Publication Name: The Tribune

Publication Date: 09/10/2026

Language: English

Edition: Himachal

Page No: 11

CCM: 160.36

Centre to cap trade margin...

down prices of 110 anti-cancer drugs, including 35 patented medicines.

"To ensure the continued availability of these life-saving drugs, manufacturers will be required to maintain current production levels. Further, manufacturers' selling prices or revenue will not be affected as the cap applies only to the trade margin," sources said.

The sources said the proposed trade margin rationalisation was expected to result in a reduction of up to 70 per cent in MRPs. "The measure is expected to result in annual savings of Rs 2,500 crore and reduce out-of-pocket expenditure for cancer patients. It will also address the issue of profiteering at the cost of patients and correct market distortions, thereby ensuring fair prices," the sources said.

Official estimates suggest that approximately 60 persons per one lakh population are affected by cancer. The treatment for cancer is associated with high financial burden and significant out-of-pocket expenditure (about 75 per cent of the total expenditure). The market data indicates that the anti-cancer medicines market comprises approximately 225 drugs and 500 formulations, with an annual turnover of around Rs 12,500 crore. Scheduled anti-cancer medicines account for approximately Rs 2,250 crore.

An analysis of the market data by the National Pharmaceutical Pricing Authority revealed that the average trade mark-up on the non-scheduled anti-cancer drugs is approximately 170 per cent, with mark-ups reaching up to 700 per cent in certain cases.

Significant price difference is also observed between the prices charged through retail, hospital and online pharmacies. Sources said serious concerns had also been raised by various state authorities (including Maharashtra, Rajasthan and Karnataka), patients and civil society through public platforms regarding excessive pricing of drugs, particularly highlighting the wide disparity between the procurement price and the MRP charged from consumers.

Summary:

The Central Government, through the National Pharmaceutical Pricing Authority (NPPA), has decided to cap trade margins at 30% for all non-scheduled anti-cancer drugs to curb profiteering. Reported by journalist Aksheev Thakur, this initiative covers domestic, imported, branded, and generic medicines, aiming to reduce MRPs by up to 70% and save patients across India approximately Rs 2,500 crore annually.

Publication Name: The Hindu Business Line
Publication Date: 09/10/2026
Language: English
Edition: Delhi
Page No: 12
CCM: 328.7

Cancer drug prices likely to fall as govt caps trade margins at 30% of MRP

COST RELIEF. The move could result in annual savings of around ₹2,500 crore for patients

Ankita Upadhyay
New Delhi

In a move aimed at reducing high mark-ups and lowering the financial burden on patients undergoing cancer treatment, the government has decided to cap trade margins at 30 per cent of the maximum retail price (MRP) for all non-scheduled anti-cancer drugs.

The measure will cover all non-scheduled anti-cancer drugs — branded, generic, domestically manufactured, imported, patented and non-patented.

Officials said a committee formed by the Union Ministry of Health and Family welfare will finalise the list of drugs. "So far, a total of 110 drugs have been identified, of which 35 are patented," the official added. The process is expected to be completed within the next 7-10 days. The government estimates that the move could reduce the MRP of affected medicines by up to 70 per cent and result in annual savings of around ₹2,500 crore for patients undergoing cancer treatment.

POSITIVE LIST

The list of medicines to be covered will be a positive list to be finalised by an expert committee under the Directorate General of Health Services. The government has also clarified that manufacturers' selling prices or revenue will not be affected by the measure, as the intervention is aimed specifically at capping trade margins.

According to the government, around 60 people per one lakh population are affected by cancer in India,



WELCOME MOVE. The measure will cover all non-scheduled anti-cancer drugs

while out-of-pocket expenditure accounts for around 75 per cent of total cancer-care expenditure. Market data cited by the government shows that the anti-cancer medicines market comprises around 225 drugs and 500 formulations, with an annual turnover of approximately ₹12,500 crore. Scheduled cancer medicines account for around ₹2,250 crore of this market.

An analysis by the National Pharmaceutical Pricing Authority (NPPA) found that the average trade mark-up on non-scheduled anti-cancer drugs is around 170 per cent, with mark-ups reaching as high as 700 per cent in some cases.

Concerns have been raised by State authorities, including Maharashtra, Rajasthan and Karnataka, as well as patients and civil society groups, over excessive drug prices and the disparity between procurement prices and the MRP charged to consumers. The government said high trade mark-ups, particularly on high-value oncology medicines, place a substantial burden on patients through out-of-pocket expenditure.

The latest decision builds on an intervention introduced by the NPPA in February 2019, when trade margins on 42 selected non-scheduled anti-cancer drugs were capped on a pilot basis by invoking extraordinary powers under Paragraph 19 of the Drugs (Prices Control) Order, 2013.

Drawing on the experience of the earlier intervention, the government has now decided to extend trade-margin rationalisation to all non-scheduled anti-cancer drugs covered by the forthcoming positive list.

Summary:

• The Union Ministry of Health and Family Welfare has capped trade margins for non-scheduled anti-cancer drugs at 30% of MRP.
• This initiative aims to reduce the financial burden on cancer patients in India by lowering drug prices.
• The NPPA will oversee the implementation, potentially saving patients ₹2,500 crore annually.

Publication Name: The Hindu Business Line
Publication Date: 09/10/2026
Language: English
Edition: Hyderabad
Page No: 12
CCM: 328.7

Cancer drug prices likely to fall as govt caps trade margins at 30% of MRP

COST RELIEF. The move could result in annual savings of around ₹2,500 crore for patients

Ankita Upadhyay
New Delhi

In a move aimed at reducing high mark-ups and lowering the financial burden on patients undergoing cancer treatment, the government has decided to cap trade margins at 30 per cent of the maximum retail price (MRP) for all non-scheduled anti-cancer drugs.

The measure will cover all non-scheduled anti-cancer drugs — branded, generic, domestically manufactured, imported, patented and non-patented.

Officials said a committee formed by the Union Ministry of Health and Family welfare will finalise the list of drugs. "So far, a total of 110 drugs have been identified, of which 35 are patented," the official added. The process is expected to be completed within the next 7-10 days. The government estimates that the move could reduce the MRP of affected medicines by up to 70 per cent and result in annual savings of around ₹2,500 crore for patients undergoing cancer treatment.

POSITIVE LIST

The list of medicines to be covered will be a positive list to be finalised by an expert committee under the Directorate General of Health Services. The government has also clarified that manufacturers' selling prices or revenue will not be affected by the measure, as the intervention is aimed specifically at capping trade margins.

According to the government, around 60 people per one lakh population are affected by cancer in India,



WELCOME MOVE. The measure will cover all non-scheduled anti-cancer drugs

while out-of-pocket expenditure accounts for around 75 per cent of total cancer-care expenditure. Market data cited by the government shows that the anti-cancer medicines market comprises around 225 drugs and 500 formulations, with an annual turnover of approximately ₹12,500 crore. Scheduled cancer medicines account for around ₹2,250 crore of this market.

An analysis by the National Pharmaceutical Pricing Authority (NPPA) found that the average trade mark-up on non-scheduled anti-cancer drugs is around 170 per cent, with mark-ups reaching as high as 700 per cent in some cases.

Concerns have been raised by State authorities, including Maharashtra, Rajasthan and Karnataka, as well as patients and civil society groups, over excessive drug prices and the disparity between procurement prices and the MRP charged to consumers. The government said high trade mark-ups, particularly on high-value oncology medicines, place a substantial burden on patients through out-of-pocket expenditure.

The latest decision builds on an intervention introduced by the NPPA in February 2019, when trade margins on 42 selected non-scheduled anti-cancer drugs were capped on a pilot basis by invoking extraordinary powers under Paragraph 19 of the Drugs (Prices Control) Order, 2013.

Drawing on the experience of the earlier intervention, the government has now decided to extend trade-margin rationalisation to all non-scheduled anti-cancer drugs covered by the forthcoming positive list.

Summary:

• The Union Ministry of Health and Family Welfare has capped trade margins for non-scheduled anti-cancer drugs at 30% of MRP.
• This initiative aims to reduce the financial burden on cancer patients in India by lowering drug prices.
• The NPPA will oversee the implementation, potentially saving patients ₹2,500 crore annually.

Publication Name: Business Standard
Publication Date: 09/10/2026
Language: English
Edition: Delhi
Page No: 13
CCM: 389.3

Govt to cap trade margins on non-scheduled cancer drugs

Move could cut prices by up to 70%

SANKET KOUL
New Delhi, 8 October

The Centre has decided to cap trade margins for all non-scheduled cancer drugs at 30 per cent of the maximum retail price (MRP), according to two senior officials aware of the matter.

"This would cover 110 non-scheduled cancer drugs, including branded, generic, domestic and imported drugs. Thirtyfive of these are patented cancer medicines," one of the officials in the know said.

The move is expected to reduce MRPs of cancer drugs by 20 to 70 per cent and generate annual savings of ₹,500 crore, another official told *Business Standard* on the condition of anonymity.

The decision aims to curb excessive trade mark-ups and improve affordability while ensuring the continued availability of these life-saving medicines, officials said.

An expert committee of the Directorate General of Health Services (DGHS) is estimating the number of brands that will come under the proposed cap. "Cancer drug brands that are expensive for the consumers are being considered for margin capping," the first official quoted above said.

He added the cancer medicine market comprises around 225 drugs and 500 formulations, with an annual turnover of around ₹12,500 crore.

A market study by the National Pharmaceutical Pricing Authority (NPPA) has found trade margins ranging from 170 to 700 per cent for cancer drugs at various outlets, the official added.

Non-scheduled drugs are pharmaceutical formulations not subject to price ceilings under the Drugs Prices Control Order (DPCO), 2013. Manufacturers of such formulations and devices can increase prices by up to 10 per cent over a rolling 12-month period. These drugs account for an estimated 82 per cent of India's domestic pharma market.

The decision marks a first step towards trade margin rationalisation (TMR), and comes even as the Department of Pharmaceuticals (DoP) and the NPPA held industry consultations on price mark-ups for essential medicines.

Under TMR, the difference between the price charged by a manufacturer to a distributor and the price paid by a consumer could be regulated, unlike conventional price controls that fix a ceiling for a formulation.

The move also comes amid Supreme Court scrutiny of high mark-ups on essential medicines. A Bench of Justices Vikram Nath and Sandeep Mehta has questioned the regulatory distinction between scheduled and non-scheduled medicines under the DPCO, and whether medicines classified as non-essential should remain outside price control mechanisms. The next hearing is scheduled for October 12.

Several state drug regulatory bodies, including those of Maharashtra, Karnataka and Uttar Pradesh, have flagged high local price mark-ups. Last month, the Maharashtra Food and Drug Administration wrote to the NPPA highlighting mark-ups of almost 1,000 per cent in the MRPs of certain medical consumables sold at hospital pharmacies, compared with their procurement costs.

The Centre had earlier capped trade margins for 42 cancer drugs in 2019, resulting in reported annual savings of ₹984 crore across 526 brands.

Officials said margin capping could eventually be extended beyond cancer drugs to other non-scheduled formulations, medical consumables and devices such as intravenous (IV) kits and catheters.

The DoP had told the Parliamentary Standing Committee on Chemicals and Fertilisers in August that it was examining a proposal to incorporate TMR into the DPCO. No timeframe had been set for the broader framework.

While pharmaceutical industry associations and consumer groups have supported the proposed TMR framework, they have recommended changes to the method of calculating margins, the proposed cap, phased implementation and the period of sales data to be considered.

More on Business-standard.com

What it entails



- 110 non-scheduled cancer drugs, including 35 patented meds, to come under proposed 30 per cent trade margin cap
- Move could cut MRPs by up to 70 per cent, save patients an estimated ₹2,500 cr annually
- NPPA study found 170-700% trade margins on cancer drugs at various outlets
- Centre had capped margins on 42 cancer drugs in 2019, saving ₹984 cr across 526 brands
- TMR could eventually extend to other non-scheduled drugs, medical devices

Summary:

• The Indian government plans to cap trade margins on 110 non-scheduled cancer drugs at 30% to improve affordability.
• The National Pharmaceutical Pricing Authority (NPPA) aims to reduce MRPs by up to 70%, potentially saving ₹5,500 crore annually.
• This initiative follows Supreme Court scrutiny regarding high mark-ups on essential medicines and medical consumables.

Publication Name: Financial Express
Publication Date: 09/10/2026
Language: English
Edition: Delhi
Page No: 1
CCM: 30.02

Prices of 110 anti-cancer drugs to fall

THE CENTRE IS set to cap trade margins at 30% on 110 non-scheduled anti-cancer drugs, including 35 patented medicines, sources in the Department of Pharmaceuticals (DoP) told *FE*, reports **Manu Kaushik.** ■ PAGE 4

Related News:

Publication Name: Financial Express

Publication Date: 09/10/2026

Language: English

Edition: Delhi

Page No: 6

CCM: 262.45

Prices of 110 anti-cancer drugs to fall sharply

MANU KAUSHIK
New Delhi, October 8

THE GOVERNMENT IS set to cap trade margins at 30% on 110 non-scheduled anti-cancer drugs, including 35 patented medicines, sources in the Department of Pharmaceuticals (DoP) told *FE*. The move could make these high-priced medicines more affordable to consumers.

The government estimates that the cap could cut the maximum retail prices (MRPs) of these drugs by up to 70% and save patients an estimated ₹2,500 crore annually. The tighter margin ceiling is also likely to pressure retailers, hospital chains and pharma companies that earn higher margins on these drugs.

"These non-scheduled drugs were not under any caps before. A committee under the Director General of Health Services (DGHS) will examine and finalise the list of medicines to be covered. The move will cover generics, patented, imported and locally-produced drugs," the DoP official said.

Non-scheduled drugs are medicines whose prices are not directly fixed by the government. Scheduled drugs, in contrast, are subject to government-controlled price limits under the Drugs (Prices Control) Order, 2013 (DPCO). The scheduled list is based on medicines included in the National List of Essential Medicines (NLEM).

According to the official, the government plans to complete the exercise within 10 days.

BIG RELIEF



- List includes 35 patented medicines
- Govt estimates MRPs could fall by up to **70%**
- Patients could save an estimated ₹2,500 cr annually
- Cap will cover generic, patented, imported, locally produced drugs

The announcement comes as the Supreme Court is examining the issue of high medicine mark-ups.

During a recent hearing, the court questioned why a cancer drug supplied to a retailer for around ₹2,700 had an MRP of ₹27,000 – a tenfold difference. The bench also questioned whether a uniform margin should apply across medicines and asked the central government to examine the issue. The matter is scheduled for further hearing on October 12.

A pharma association official said the proposal would limit retailers' margins by restricting the difference between the price paid by the retailer and the MRP to 30%. "This cap will be applicable on the retailers' margins. The difference between PTR and MRP cannot be more than 30% now.

"There's already a 16% cap on trade margins on the scheduled drugs across the board. The move is likely to affect retailers, hospital chains and pharma companies, especially those who work on high margins," he said.

Under the existing framework, the scheduled drugs are subject to government-regulated trade margins when their ceiling prices are fixed.

Summary:

The Department of Pharmaceuticals (DoP) is set to cap trade margins at 30% for 110 non-scheduled anti-cancer drugs, an initiative reported by Manu Kaushik. This government measure, currently under review by the Supreme Court, aims to reduce MRPs by up to 70%, potentially saving patients ¹2,500 crore annually by regulating prices on essential cancer medications.

Publication Name: Mint
Publication Date: 09/10/2026
Language: English
Edition: Delhi
Page No: 2
CCM: 202.15

Centre plans 30% margin cap on key cancer medicines

Priyanka Sharma
priyanka.sharma@livemint.com
NEW DELHI



Centre's move could cut retail prices by as much as 70%. AP

The Centre is preparing to cap trade margins on all non-scheduled anti-cancer medicines at 30% of their maximum retail price (MRP), a move that could cut retail prices by as much as 70% and save cancer patients an estimated ₹2,500 crore to ₹3,500 crore a year, according to three senior government officials familiar with the matter.

The order is expected soon, ahead of a Supreme Court hearing on 12 October, where the government is expected to present its framework for making cancer therapies more affordable.

The proposed cap would cover branded and generic drugs, domestically produced and imported medicines, and patented and non-patented drugs, the officials said. It would target trade mark-ups between manufacturers and retail points such as hospitals rather than manufacturers' selling prices, they said.

The move comes as cancer treatment remains a major burden on Indian households, with out-of-pocket spending accounting for about 75% of total cancer treatment expenses. Cancer incidence in India is approximately 60 per 100,000 population, according to data cited by the government.

The broader anti-cancer medicines market comprises approximately 225 drugs and 500 formulations, with annual turnover of around ₹12,500 crore, according to industry data. Scheduled medicines account for nearly ₹2,250 crore.

The proposed trade margin rationalization (TMR) targets non-scheduled anti-cancer drugs, which fall outside the direct price ceiling under the National List of Essential Medicines (NLEM).

"Studies by market data groups and the National Pharmaceutical Pricing Authority (NPPA) revealed staggering trade margins ranging from an average of 170% to up to 700% on cancer therapies, leaving patients vulnerable to excessive retail mark-ups by distributors and private hospitals," one of the three officials cited earlier said.

For an extended version of this story, go to livemint.com.

Summary:

The Central Government plans to cap trade margins on non-scheduled anti-cancer medicines at 30% to reduce retail prices by up to 70%. This initiative, overseen by the National Pharmaceutical Pricing Authority (NPPA), aims to alleviate the financial burden on Indian households. The government will present this framework for affordable cancer therapy during an upcoming Supreme Court hearing.

Publication Name: Hindustan
Publication Date: 09/10/2026
Language: Hindi
Edition: Bareilly
Page No: 17
CCM: 98.67

30 percent profit margin to be fixed on 68 cancer drugs

कैंसर की 68 दवाओं पर 30 फीसदी का मुनाफा तय होगा

फैसला

नई दिल्ली, विशेष संवाददाता। सुप्रीम कोर्ट की तीखी टिप्पणी के बाद केंद्र सरकार ने कैंसर की 68 दवाओं पर मुनाफे की सीमा तय करने का फैसला किया है। सरकार ने कहा कि इन दवाओं के अधिकतम विक्रय मूल्य (एमआरपी) में 30 फीसदी तक ही मुनाफा लिया जा सकेगा। यानी कंपनी द्वारा 70 रुपये में बेची जाने वाली दवा की एमआरपी 100 रुपये से अधिक नहीं होगी।

रसायन एवं उर्वरक मंत्रालय के सूत्रों ने कहा कि अगले 10 दिनों के भीतर इन दवाओं की सूची जारी की जाएगी। इनमें 35 पेटेंट हुई दवाएं भी शामिल हैं। बाकी जेनेरिक और ब्रांडेड श्रेणी की हैं। कुछ आयातित दवाओं पर भी यही नियम लागू होगा। ये सभी गैर अधिसूचित दवाएं हैं, यानी मौजूदा मूल्य नियंत्रण की सूची में नहीं हैं। नई सूची जारी होने के बाद कैंसर की कुल 110 दवाओं पर अधिकतम मुनाफे की सीमा तय हो जाएगी। इससे पहले सरकार ने 2019 में भी 42 कैंसररोधी दवाओं का ट्रेड मार्जिन तय किया था, जिससे उपभोक्ताओं को 526 करोड़ी की बचत का अनुमान है। सरकार के नए कदम से 2500 करोड़ रुपये की बचत होगी।

Summary:

- The Central Government, following Supreme Court remarks, capped profit margins at 30% for 68 cancer drugs.
- The Ministry of Chemicals and Fertilizers will release a list of 110 total drugs under price control.
- This initiative is expected to save consumers 2500 crore rupees, building on a 2019 policy for 42 anti-cancer drugs.

Publication Name: Navbharat Times
Publication Date: 09/10/2026
Language: Hindi
Edition: Faridabad
Page No: 3
CCM: 51.28

SC strict to stop 'freebies' of pharma companies

दवा कंपनियों की 'फ्रीबी' रोकने के लिए SC सख्त

■ NBT रिपोर्ट, नई दिल्ली: दवाओं की बिक्री बढ़ाने के लिए डॉक्टरों को महंगे तोहफे, कैश, विदेश यात्रा और दूसरी सुविधाएं देने की प्रथा पर रोक लगाने की दिशा में सुप्रीम कोर्ट ने बड़ा कदम उठाया है। कोर्ट ने केंद्र सरकार को विशेष कमिटी बनाने का आदेश दिया है। कमिटी फार्मा कंपनियों की अनैतिक मार्केटिंग प्रथाओं को रोकने के लिए कानूनी प्रावधानों पर सुझाव देगी। केंद्र को कमिटी की प्रगति पर कोर्ट में हलफनामा दाखिल करना होगा। याचिकाकर्ताओं ने कहा कि इस असमानता के कारण कंपनियां डॉक्टरों के प्रिस्क्रिप्शन को प्रभावित कर सकती हैं। अगली सुनवाई 29 जनवरी को होगी। ▸▸ शेष पेज 13 पर

कोर्ट ने केंद्र को विशेष कमिटी बनाने का दिया निर्देश

Summary:

• The Supreme Court has ordered the Central Government to form a special committee to curb unethical marketing practices by pharma companies.
• The committee will propose legal measures to stop companies from influencing doctors with gifts and cash.
• The Center must report progress to the Supreme Court before the next hearing on January 29.

Publication Name: Dainik Jagran
Publication Date: 09/10/2026
Language: Hindi
Edition: Siliguri
Page No: 13
CCM: 332.51

Supreme Court to curb unethical marketing practices of pharma companies: Maximum 30% margin fixed on 110 cancer drugs

फार्मा कंपनियों के मार्केटिंग के अनैतिक तरीकों पर लगेगी लगाम : सुप्रीम कोर्ट

नई दिल्ली, प्रेट्र: सुप्रीम कोर्ट ने फार्मा कंपनियों के मार्केटिंग के अनैतिक तरीकों पर रोक लगाने के लिए गुरुवार को केंद्र सरकार को एक समिति गठित करने का निर्देश दिया। यह समिति सुझावों पर विचार कर सरकार को सिफारिश करेगी ताकि फार्मा कंपनियों की ऐसी गतिविधियों पर लगाम कसी जा सके।

बता दें कि फार्मा कंपनियां अपने उत्पादों के प्रचार के लिए चिकित्सकों को महंगे गिफ्ट व अन्य कई तरह के लाभ प्रदान करती हैं। यहां तक कि कुछ तो चिकित्सकों के विदेश भ्रमण और उनके स्वजनों तक का सारा खर्चा उठाती हैं। ओवरआल इसका असर मरीज और उसके स्वजनों पर पड़ता है और उन्हें महंगी दवाएं खरीदने के लिए मंजूर होना पड़ता है। न्यायमूर्ति विक्रम नाथ और संदीप मेहता की पीठ ने एक याचिका पर यह आदेश दिया। याचिका में मांग की गई थी कि प्रभावी कानून बनने तक शीर्ष अदालत फार्मास्यूटिकल कंपनियों की अनैतिक मार्केटिंग गतिविधियों पर नियंत्रण और नियमन के लिए दिशा-निर्देश तय करे। याचिकाकर्ता की ओर से कहा गया कि मौजूदा व्यवस्था में असमानता है। इसके तहत ऐसे प्रलोभन स्वीकार करने वाले डाक्टरों के लिए कार्रवाई का प्रविधान तो है, लेकिन उन्हें देने वाली दवा कंपनियों को नियंत्रित करने या दंडित करने के लिए समान वैधानिक व्यवस्था नहीं है। केंद्र ने आठ सितंबर को शीर्ष अदालत को बताया था कि फार्मास्यूटिकल कंपनियों को अनैतिक गतिविधियों से रोकने के लिए वैधानिक ढांचा सुझाने हेतु उसने तीन सदस्यीय समिति गठित करने का फैसला लिया है। केंद्र ने यह भी माना कि यह सुनिश्चित करने के लिए व्यवस्था को मजबूत करने की जरूरत है कि फार्मास्यूटिकल कंपनियां किसी भी अनैतिक गतिविधि में शामिल न हों। केंद्र ने कहा था कि समिति की रिपोर्ट मिलने और उसके आधार पर फैसला होने तक 'यूनिफार्म कोड फार फार्मास्यूटिकल मार्केटिंग प्रैक्टिसेज, 2024' लागू रहेगा।

- सुप्रीम कोर्ट ने इस संबंध में केंद्र सरकार को एक समित गठित करने का निर्देश दिया
- समिति मार्केटिंग के अनैतिक तरीकों पर रोक लगाने के बारे में देगी सिफारिशें



110 कैंसर दवाओं पर अधिकतम 30% मार्जिन तय

नई दिल्ली, प्रेट्र: कैंसर की महंगी दवाओं पर मरीजों को बड़ी राहत मिलने की उम्मीद है। सरकार ने सभी गैर-अनुसूचित कैंसर दवाओं के ट्रेड मार्जिन को एमआरपी (अधिकतम खुदरा मूल्य) के 30 प्रतिशत तक सीमित करने का फैसला किया है। इससे करीब 110 कैंसररोधी दवाओं की कीमतों में कमी आने की संभावना है। इनमें 35 पेटेंट वाली दवाएं भी शामिल हैं। आइएएनएस ने सूत्रों के हवाले से बताया कि इस फैसले से दवाओं की कीमत में 70 प्रतिशत तक की कमी आ सकती है।

यह सीमा ब्रांडेड और जेनेरिक, घरेलू और आयातित तथा पेटेंट वाली और बिना पेटेंट वाली दवाओं पर लागू होगी। सरकार का उद्देश्य कैंसर की जीवनरक्षक दवाओं की कीमतों में व्यापार स्तर पर होने वाली अत्यधिक बढ़ोतरी पर रोक लगाना और उन्हें मरीजों के लिए अधिक किफायती बनाना है। साथ ही, बाजार में इन दवाओं की उपलब्धता बनाए रखने पर भी जोर रहेगा। इस फैसले को इसी महीने के अंत तक लागू किए जाने की उम्मीद है। सूत्रों के अनुसार, ट्रेड मार्जिन रैशनलाइजेशन का मुख्य मकसद गलत तरीके से दवाएं बेचने की प्रथाओं को रोकना है। अमूमन देखा जाता है कि कारोबारियों का जोर ज्यादा मार्जिन वाली दवाओं को बेचने पर अधिक रहता है। चूंकी कैंसर दवाएं महंगी होती हैं, इसलिए उन पर ट्रेड मार्जिन की सीमा तय करना जरूरी था। इस कदम से कैंसर के मरीजों की सालाना लगभग 2500 करोड़ रुपये की बचत होगी। सुप्रीम कोर्ट ने भी पिछले महीने कैंसर दवाओं की बहुत ज्यादा बेतहाशा कीमतों पर गंभीर चिंता जताई थी। सभी दवाओं पर एक समान 16 प्रतिशत मार्जिन की वकालत करते हुए, जस्टिस विक्रम नाथ और जस्टिस संदीप मेहता की बेंच ने सालिसिटर जनरल तुषार मेहता से इसे खुली लूट बताया था। उन्होंने कहा था कि कैंसर की दवा फुटकर दवा विक्रेताओं को 2,700 रुपये में सप्लाई की जाती है, फिर भी उसकी एमआरपी 27,000 रुपये है।

70% तक घट सकती हैं कीमतें, गैर अनुसूचित दवाओं पर ट्रेड मार्जिन की सीमा तय, 35 पेटेंट दवाएं भी शामिल

Summary:

• The Supreme Court directed the Central Government to form a committee to curb unethical marketing by pharma companies and implement a uniform code.
• The government capped trade margins on 110 cancer drugs at 30% of MRP to make them affordable.
• This initiative is expected to save cancer patients approximately ₹2500 crore annually.

Publication Name: Dainik Bhaskar
Publication Date: 09/10/2026
Language: Hindi
Edition: Indore
Page No: 1
CCM: 75.27

Central government in action after Supreme Court's query: 110 cancer drugs to become up to 70% cheaper, trade margin to be capped at 30%

सुप्रीम कोर्ट के सवाल के बाद केंद्र सरकार हरकत में

कैंसर की 110 दवाएं 70% तक सस्ती होंगी, ट्रेड मार्जिन 30% तक घटेगा

नई दिल्ली | कैंसर के महंगे इलाज से जूझ रहे लाखों मरीजों को बड़ी राहत मिलने वाली है। केंद्र सरकार ने कैंसर की दवाओं पर ट्रेड मार्जिन यानी कंपनियों से खुदरा बिक्री तक होने वाले मुनाफे को एमआरपी के 30% तक सीमित करने का फैसला किया है। इससे कैंसर की 110 दवाओं की कीमतें कम होने की उम्मीद है। कुछ दवाएं 70% तक सस्ती हो सकती हैं। इस फैसले से मरीजों के सालाना 2500 करोड़ रु. बचेंगे। नई व्यवस्था इसी महीने लागू हो सकती है। रसायन और उर्वरक मंत्रालय के अधीन औषध विभाग अगले दस दिन में कीमतों में कटौती की घोषणा कर सकता है। सुप्रीम कोर्ट द्वारा कुछ कैंसर दवाओं के खुदरा विक्रेता मूल्य (पीटीआर) व अधिकतम खुदरा मूल्य (एमआरपी) के बीच भारी अंतर पर सवाल उठाने के बाद यह राहत मिलने जा रही है।

Summary:

• The Central Government, following a Supreme Court query, decided to cap trade margins on 110 cancer drugs at 30% of MRP.
• This initiative by the Ministry of Chemicals and Fertilizers is expected to make drugs up to 70% cheaper.
• The move aims to provide significant financial relief to cancer patients across India.

Publication Name: Amar Ujala
Publication Date: 09/10/2026
Language: Hindi
Edition: Delhi
Page No: 18
CCM: 1119.08

Cancer drugs to be up to 70% cheaper; trade margin capped at 30%

70% तक सस्ती होंगी कैंसर की दवाएं व्यापार मार्जिन की सीमा 30% तय

केंद्र सरकार का आदेश इस माह के अंत से हो सकता है लागू

नई दिल्ली। केंद्र सरकार ने कैंसर के इलाज में इस्तेमाल होने वाली सभी गैर-अनुसूचित दवाओं पर ट्रेड मार्जिन अधिकतम खुदरा मूल्य (एमआरपी) का 30 फीसदी तक करने का फैसला किया है। सरकार के इस फैसले से कैंसर की दवाएं 70 फीसदी तक सस्ती हो सकती हैं, जिससे आम मरीजों को बड़ी राहत मिलेगी।

सूत्रों के मुताबिक, इस नई व्यवस्था ब्रांडेड, जेनेरिक, घरेलू, आयातित, पेटेंट और गैर-पेटेंट समेत कैंसर की सभी श्रेणियों की लगभग 110 दवाओं पर समान रूप से लागू होगी, जिनमें 35 पेटेंट वाली दवाएं भी शामिल हैं। यह आदेश इसी महीने के अंत तक प्रभावी हो सकता है। सरकार के इस कदम से बाजार में दवाओं की निरंतर आपूर्ति सुनिश्चित रहते हुए मरीजों पर वित्तीय बोझ काफी हद तक कम होगा।

ट्रेड मार्जिन क्या है : ट्रेड मार्जिन वह अंतर है जो दवा कंपनी की ओर से पहले वितरक या स्टॉकिस्ट को बेची गई कीमत और मरीज की ओर से दवा के लिए चुकाई जाने वाली अंतिम कीमत के बीच होता है। उदाहरण के लिए यदि किसी दवा को कंपनी वितरक को 100 रुपये में बेचती है और रिटेलर उसे मरीज को 500 रुपये में बेचता है, तो बीच का 400 रुपये (400%) ट्रेड मार्जिन कहलाता है। चूंकि गैर-अनुसूचित दवाओं की शुरुआती कीमतों पर सरकार का सीधा नियंत्रण नहीं होता, इसलिए कंपनियां अपने विशिष्ट ब्रांड को बढ़ावा देने के लिए ट्रेड मार्जिन का ऑफर करती हैं। ब्यूरो



गिफ्ट देकर दवा नहीं लिखवा पाएंगी कंपनियां

नई दिल्ली। सुप्रीम कोर्ट ने दवा कंपनियों द्वारा अपनी ब्रांडेड दवाएं लिखवाने के लिए डॉक्टरों को महंगे गिफ्ट, विदेश यात्राएं और अन्य फ्रीबीज (मुफ्त सुविधाएं) देने की अनैतिक प्रथा पर बेहद सख्त रुख अपनाया है। जस्टिस विक्रम नाथ और जस्टिस संदीप मेहता की बेंच ने मामले में केंद्र सरकार को निर्देश दिया है कि वह एक विशेष कमेटी का गठन करे। यह कमेटी दवा कंपनियों की गलत और अनैतिक मार्केटिंग प्रैक्टिस को रोकने और इसे कानूनी नियमों के दायरे में लाने के लिए अपने कड़े सुझाव और सिफारिशें तैयार करेगी। यह मुद्दा ऐसे समय सामने आया है जब शीर्ष न्यायालय दवाओं की कीमत और उनकी किफायती उपलब्धता से जुड़े एक अलग मामले की भी जांच कर रहा है। ब्यूरो

जुर्माना 10,000 करोड़, 84 फीसदी अब भी जमा नहीं

नई दिल्ली (हिमांशु अरविंद मिश्र)। बेहतर इलाज के नाम पर अस्पताल पहुंचने वाले मरीजों से दवा की ऊंची कीमतों के रूप में भी लूट हो रही है। अस्पतालों की इस लूट से मरीजों को बचाने के लिए कड़े कदम भी उठाती है, लेकिन यह सिर्फ कागजों तक सिमट के रह गई है। औषधि मूल्य निर्धारण प्राधिकरण (एनपीपीए) के आंकड़े बताते हैं कि दवा की ज्यादा कीमत वसूलने पर कंपनियों पर इस साल 31 मार्च तक 10,029 करोड़ रुपये जुर्माना लगाया गया, लेकिन वसूली सिर्फ 1,582.4 करोड़ रुपये की हो सकी, यानी 8,447.4 करोड़ रुपये (84 फीसदी) अब भी बाकी हैं। उत्तर प्रदेश में अस्पतालों की तरफ से 67 फीसदी और कर्नाटक में 52 फीसदी ज्यादा कीमत वसूलने के मामले सामने आए हैं।

बड़े मामलों में सिप्ला समेत कई कंपनियां

कंपनीवार रिकॉर्ड में सिप्ला, जॉनसन एंड जॉनसन, रैनबैक्सी, ग्लैक्सोस्मिथक्लाइन और सन फार्मा जैसी कंपनियों के खिलाफ बड़ी रकम के मामले दर्ज हैं। सिप्ला के एक सालबुटामोल मामले में ब्याज समेत 742.82 करोड़ रुपये की जुर्माना दर्ज है, जिसमें 93.96 करोड़ रुपये वसूले जा चुके हैं।

Summary:

The Central Government has capped trade margins on cancer drugs at 30%, potentially reducing prices by 70%. The Supreme Court has also ordered a committee to curb unethical marketing practices by pharmaceutical companies. Meanwhile, the NPPA reports that 84% of fines imposed on drug companies for overcharging remain unrecovered, highlighting ongoing issues with hospital and pharmaceutical pricing.

Publication Name: Punjab Kesari
Publication Date: 09/10/2026
Language: Hindi
Edition: Chandigarh
Page No: 1
CCM: 175.97

Shooter Parminder Kaka arrested in 'Mad Sandhu' murder case; Sellers will not be able to charge more than 30% profit on cancer drugs!

'मैड संधू' की हत्या के मामले में शूटर परमिंदर काका गिरफ्तार

अहमदाबाद, 8 अक्तूबर (एजैंसी): अहमदाबाद अपराध शाखा ने पंजाबी सोशल मीडिया इन्फ्लुएंसर और मेकअप आर्टिस्ट मैड संधू की इस महीने की शुरूआत में अमृतसर में हुई हत्या में संलिप्तता के आरोप में एक शख्स को गिरफ्तार किया है।



पुलिस ने बृहस्पतिवार को यह जानकारी दी। पुलिस उपायुक्त (अपराध) अजित राजियन ने बताया कि आरोपी की पहचान परमिंदर काका उर्फ परमिंदर प्रसाद के रूप में हुई है। वह कथित रूप से गोल्डी ढिल्लों गिरोह से जुड़ा था और उसने इन्फ्लुएंसर पर गोली चलाई थी।

राजियन ने कहा, 'उसकी भूमिका शूटर की है। उसने गोलीबारी की और मोटरसाइकिल की भी व्यवस्था की।' पंजाबी सोशल मीडिया इन्फ्लुएंसर और मेकअप आर्टिस्ट संधू की 3 अक्तूबर को पंजाब के अमृतसर के लोहारका रोड इलाके में गोली मारकर हत्या कर दी गई थी।

कैंसर दवाओं पर 30% से ज्यादा मुनाफा नहीं वसूल सकेंगे विक्रेता!

अत्यधिक मुनाफे को लेकर सरकार सख्त

नई दिल्ली, 8 अक्तूबर (नवोदय टाइम्स): कैंसर के इलाज का खर्च पहले ही मरीजों और परिवारों की कमर तोड़ रहा है। ऐसे में महंगी कैंसर रोधी दवाओं पर दुकानदारों और डिस्ट्रीब्यूटर के मुनाफे की सीमा तय करने का सरकार का फैसला मरीजों के लिए बड़ी राहत बनकर सामने आया है।

केंद्रीय स्वास्थ्य एवं परिवार कल्याण मंत्री जे.पी. नड्डा ने कहा है कि सरकार का जोर कैंसर जैसी गंभीर बीमारी के इलाज को अधिक किफायती बनाने पर है। गैर-अनुसूचित कैंसर रोधी दवाओं पर ट्रेड मार्जिन को 30% तक सीमित करने का फैसला किया गया है जिससे महंगी दवाओं के अधिकतम खुदरा मूल्य में 70 प्रतिशत तक कमी आने का अनुमान है। इस बारे फैसला अगले 8 से 10 दिन में पूर्णतया लागू हो जाएगा।

मरीजों को सालाना 2500 करोड़ की होगी बचत

सरकार के अनुमान के मुताबिक इस कदम से कैंसर मरीजों को सालाना करीब 2500 करोड़ रुपए की बचत होगी। यह 2019 में उठाए गए कदम का विस्तार है, जब 526 ब्रांड की कैंसर दवाओं पर मूल्य संबंधी हस्तक्षेप से सालाना करीब 984 करोड़ रुपए की बचत सामने आई थी। हाल ही में सुप्रीम कोर्ट ने कैंसर की 2700 रुपए वाली दवा 27000 रुपए में बिकने को लेकर सवाल उठाया था।

Summary:

• Shooter Parminder Kaka was arrested by Ahmedabad Crime Branch for the murder of influencer Mad Sandhu in Amritsar.
• Union Health Minister J.P. Nadda announced a 30% cap on trade margins for anti-cancer drugs to make treatment affordable.
• This government initiative is expected to save cancer patients approximately ¹2500 crore annually.

Publication Name: Rajasthan Patrika
Publication Date: 09/10/2026
Language: Hindi
Edition: Chennai
Page No: 12
CCM: 198.12

Impact of Supreme Court's remark: MRP could be reduced by up to 70 percent. 'Robbery' of profits in cancer drugs will stop, margin will be capped at 30 percent.

सुप्रीम कोर्ट की टिप्पणी का असर : एमआरपी हो सकती 70 प्रतिशत तक कम

कैंसर दवाओं में मुनाफे की 'डकैती' रुकेगी, मार्जिन 30% सीमित होगा

पत्रिका न्यूज नेटवर्क
patrika.com

नई दिल्ली. आने वाले दिनों में महंगी कैंसर दवाओं की खुदरा कीमतों पर मुनाफाखोरी की 'दिन-दहाड़े डकैती' से मरीजों को राहत मिल सकती है। केंद्र सरकार महंगी कैंसर दवाओं पर वितरकों के मार्जिन को लागत से ऊपर 30% तक सीमित (कैपिंग) करने की तैयारी कर रही है। इससे कुछ दवाओं की एमआरपी में 70% तक कमी आने की संभावना है। प्रस्ताव में सभी गैर-अनुसूचित ब्रांडेड, जेनेरिक, घरेलू, आयातित, पेटेंट और गैर-पेटेंट उत्पादों दवाएं शामिल हैं। पिछले दिनों सुप्रीम कोर्ट ने गैर अधिसूचित कैंसर दवाओं में मुनाफाखोरी को डकैती बताते हुए कैपिंग का विचार व्यक्त किया था।



औषधि विभाग के सूत्रों के अनुसार, स्वास्थ्य सेवा महानिदेशक की अध्यक्षता वाली समिति उन दवाओं की सूची तैयार कर रही है। **शेष @ पेज 07**

पत्रिका ने उठाया था मुद्दा, सुप्रीम कोर्ट ने की थी टिप्पणी


कानून में सस्ते इलाज का रास्ता, फिर भी महंगी दवाओं के आगे बेबस मरीज

***पत्रिका** ने पिछले दिनों ही कैंसर व अन्य बीमारियों की महंगी दवाओं का मुद्दा उठाया था। प्रकाशित खबरों में मरीजों और आम आम लोगों की पीड़ा व पेटेंट के नाम पर भारी वसूली का खेल समझाया गया था। सुप्रीम कोर्ट ने पिछले माह ही एक मामले में कैंसर दवाओं अत्यधिक मुनाफाखोरी को 'दिनदहाड़े डकैती' जैसा बताया था।*

Summary:

The Central Government is set to cap distributor margins on cancer drugs at 30%, potentially reducing MRPs by 70%. This follows the Supreme Court's intervention, which labeled excessive profiteering as 'daylight robbery'. The Department of Pharmaceuticals and the Director General of Health Services are currently finalizing the list of affected drugs.

Publication Name: Andhra Jyothi
Publication Date: 09/10/2026
Language: Telugu
Edition: Visakhapatnam
Page No: 2
CCM: 182.25

Scissors on Cancer Drug Prices! 30 Percent Limit on Trade Margin: Centre.. Implementation from the end of this month

క్యాన్సర్ మందుల ధరలకు కత్తెర!

ట్రేడ్ మార్జిన్‌పై 30 శాతం పరిమితి: కేంద్రం.. ఈ నెలాఖరు నుంచి అమలు

న్యూఢిల్లీ, అక్టోబరు 8: క్యాన్సర్ బాధితులకు భారీ ఊరటనిచ్చేలా కేంద్ర ప్రభుత్వం కీలక నిర్ణయం తీసుకుంది. నాన్ షెడ్యూల్ (ధరల నియంత్రణ పరిధిలో లేని) కేటగిరీకి చెందిన అన్ని రకాల క్యాన్సర్ మందుల గరిష్ఠ అమ్మకపు ధరపై(ఎంఆర్‌పీ) ట్రేడ్ మార్జిన్‌ను 30శాతానికి పరిమితం చేయాలని నిర్ణయించింది. ఈ నిర్ణయం వల్ల దేశవ్యాప్తంగా క్యాన్సర్ రోగులకు ఏడాదికి రూ. 2,500 కోట్లు ఆదా అవుతుందని అంచనా వేస్తున్నారు. ఈ నిబంధన బ్రాండెడ్, జెనరిక్, స్వదేశీ, దిగుమతి చేసుకున్న మందులతో పాటు పేటెంటెడ్, నాన్- పేటెంటెడ్ ఔషధాలన్నింటికీ వర్తిస్తుందని ప్రభుత్వ వర్గాలు గురువారం వెల్లడించాయి. ఔషధ మార్కెట్‌లో క్యాన్సర్ మందుల సరఫరా వ్యవస్థలో వచ్చే అధిక లాభాలకు చెక్ పెట్టడంతో పాటు రోగులపై ఆర్థికభారం పడకుండా చూడటమే లక్ష్యంగా ఈ ట్రేడ్ మార్జిన్ రేషనలైజేషన్(టీఎంఆర్) విధానాన్ని తెచ్చినట్లు అధికారులు తెలిపారు. ఈ నెలాఖరు నుంచే అమల్లోకి రానున్న ఈ నిర్ణయం ద్వారా 35రకాల పేటెంట్ మందులు సహా మొత్తం 110 రకాల క్యాన్సర్ ఔషధాల ధరలు గణనీయంగా తగ్గనున్నాయి. కాగా, క్యాన్సర్ మందుల విపరీత ధరలపై ఇటీవల సుప్రీంకోర్టు ఆగ్రహం వ్యక్తం చేసింది. రీటైలర్లకు రూ.2,700కు లభించే మందును రూ. 27వేల ఎమ్మార్పీతో విక్రయించడంపై మండిపడింది. అయితే, ప్రభుత్వం తీసుకున్న నిర్ణయం తాజా కేసుతో సంబంధం లేదని, 2019 నుంచే దీనిపై కసరత్తు జరుగుతోందని కేంద్రవర్గాలు స్పష్టం చేశాయి. కాగా, ఫార్మా కంపెనీలు అనైతిక వ్యాపారాలు చేయకుండా నియంత్రించే విషయమై సిఫార్సులు చేసేందుకు కమిటీ ఏర్పాటు చేయాలని సుప్రీంకోర్టు గురువారం కేంద్రానికి సూచించింది. అనైతిక వ్యాపారాల నియంత్రణకు చట్టాన్ని రూపొందించాల్సిందిగా కేంద్రాన్ని ఆదేశించాలని కోరుతూ దాఖలైన వ్యాజ్యంపై విచారణ జరిపి ఈ సూచన చేసింది.



Summary:

• The Central Government has capped trade margins on cancer drugs at 30%, aiming to save patients Rs 2,500 crore annually.
• This policy covers 110 types of cancer drugs, including patented ones, effective from the end of this month.
• The Supreme Court urged the Centre to form a committee to curb unethical pricing practices by pharmaceutical companies.

Publication Name: Daily Thanthi
Publication Date: 09/10/2026
Language: Tamil
Edition: Bengaluru
Page No: 1
CCM: 1322.15

Cancer drug prices reduced; 30 percent cap set for retail sale; Central Government action

சுப்ரீம் கோர்ட்டு கண்டனம் எதிரொலி

சில்லறை விற்பனைக்கு 30 சதவீதமாக நிர்ணயம்

புற்றுநோய் மருந்துகள் விலை குறைகிறது

மத்திய அரசு நடவடிக்கை

சுப்ரீம் கோர்ட்டு கண்டனம் தெரிவித்த நிலையில் புற்றுநோய் மருந்துகளின் விலையை குறைக்க மத்திய அரசு நடவடிக்கை எடுத்துள்ளது. அதன்படி சில்லறை விற்பனை விலை 30 சதவீதமாக நிர்ணயம்செய்யப்பட்டுள்ளது.இதன்மூலம் மருந்துகளின் விலை 70 சதவீதம் குறையும்.

புதுடெல்லி, அக்.9-

இந்தியாவில் புற்றுநோயால் பாதிக்கப்படும் ஏழை மற்றும் நடுத்தர குடும்பங்கள், மருந்துகளின் அதிக விலை உயர்வால்பெரும்பொருளாதார நெருக்கடிக்கு ஆளாகி வருகின்றன.

கொள்ளை லாபம்

பல நேரங்களில் மருந்து வாங்க பணமில்லாமல், நோயாளிகள் சிகிச்சையையே பாதியில் கைவிடும் அவல நிலையும், இதனால் ஏற்படும் மரணங்களும் தொடர்கதையாகி வருகின்றன.

இந்த நிலையில், புற்றுநோய் மருந்துகளின் அசல் விலைக்கும், சந்தையில் விற்கப்படும் அதிகபட்ச விற்பனை விலைக்கும் இடையே உள்ள அநியாயமான கொள்ளை லாப வித்தியாசம் குறித்த வழக்கு அண்மையில் சுப்ரீம் கோர்ட்டில் விசாரணைக்கு வந்தது.

கடும் கண்டனம்

அப்போது நீதிபதிகள், "உயிர்காக்கும் மருந்துகளின் இந்த ராக்கெட் வேக விலை உயர்வு,சாதாரண மக்களுக்கு கடும்பாதிப்பைஏற்படுத்தும். இது பகல்கொள்ளை, படுகொலைக்கு சமமானது" என்று மிகக்கடுமையான கண்டனத்தைதெரிவித்தனர்.

மேலும், கோர்ட்டு விசாரணையின்போது, மருந்து நிறுவனங்கள் தயாரிப்பாளர்களிடம் இருந்து வெறும் ரூ.2 ஆயிரத்து 700-க்கு வாங்கும் ஒரு முக்கிய புற்றுநோய் மருந்தை, நோயாளிகளுக்கு ரூ.27 ஆயிரம் என்ற அநியாய விலைக்குவிற்பனைசெய்வது ஆதாரங்களுடன் சுட்டிக்காட்டப்பட்டது. இதனால் அதிர்ச்சி அடைந்த சுப்ரீம் கோர்ட்டு, மத்திய அரசு உடனடியாக ஒரு உயர்மட்டகுழுவை அமைத்து, புற்றுநோய் மருந்துகளின் விலையை குறைக்க போர்க்கால அடிப்படையில் நடவடிக்கைஎடுக்கவேண்டும்என அதிரடியாக உத்தரவிட்டது.

30 சதவீத லாப வரம்பு

சுப்ரீம் கோர்ட்டின் இந்த அதிரடி வலியுறுத்தலையும், சாட்டையடி உத்தரவையும் தொடர்ந்து, மத்திய சுகாதாரத்துறை மற்றும் தேசிய மருந்து விலை கட்டுப்பாட்டு வாரியம் இணைந்து புதிய அதிரடி உத்தரவை பிறப்பித்துள்ளது.

இதன்படி,புற்றுநோய்மருந்துகளின் வணிக லாப வரம்பை அதன் அதிகபட்ச சில்லறைவிலையில்30 சதவீதமாக குறைத்து மத்திய அரசு அதிரடி உச்சவரம்பு நிர்ணயம் செய்துள்ளது.

மத்திய அரசின் இந்த புதிய விலை கட்டுப்பாட்டுவிதியானது, தேசிய அத்தியாவசிய மருந்துகள் பட்டியலில் இல்லாத 110 வகையான முக்கிய புற்றுநோய் மருந்துகளுக்கு பொருந்தும். இதில் உள்நாட்டு 'பிராண்டட்' மற்றும் 'ஜெனரிக்' மருந்துகள் மட்டுமின்றி, வெளிநாடுகளில் இருந்து இறக்குமதி செய்யப்படும் 35 காப்புரிமை பெற்ற அதிநவீன புற்றுநோய் மருந்துகளும் அடங்கும் என்பது குறிப்பிடத்தக்கது.

ரூ.2,500 கோடி மிச்சமாகும்

மத்திய அரசின் இந்த அதிரடி நடவடிக்கையால், சந்தையில் விற்கப்படும் அத்தனை முக்கிய புற்றுநோய் மருந்துகளின் விலையும் 70 சதவீதம் வரை சரியப்போகிறது. இதன் மூலம், இந்தியாவில் உள்ளலட்சக்கணக்கான புற்றுநோய் நோயாளிகள் மற்றும் அவர்தம் குடும்பத்தினருக்கு ஒட்டுமொத்தமாக ஆண்டுக்கு சுமார் ரூ.2 ஆயிரத்து 500 கோடி வரை மருத்துவச்செலவு மிச்சமாகும் என்று மத்திய அரசு அதிகாரப்பூர்வமாக மதிப்பிட்டுள்ளது.

கடந்த 2019-ம் ஆண்டு வெறும் 42 புற்றுநோய் மருந்துகளுக்கு மட்டும் இத்தகைய லாபவரம்புசோதனைமுறையில் விதிக்கப்பட்டு ரூ.984 கோடி வரை மக்களுக்கு மிச்சப்படுத்தப்பட்டது.தற்போது சுப்ரீம்கோர்ட்டின்தலையீட்டால் இந்த விலைகுறைப்பு நடவடிக்கை விரிவுபடுத்தப்பட்டுள்ளது.

இந்த மாதம் நடைமுறைக்கு வரும்

இந்த புதிய விலை கட்டுப்பாடுஉடனடியாகஇந்தமாத இறுதிக்குள் நாடு முழுவதும் முழுமையாக அமலுக்கு வரவுள்ளதாக தகவல்கள் வெளியாகி உள்ளன. மத்திய அரசின் இந்த நடவடிக்கையால் புற்றுநோயால் பாதிக்கப்பட்டவர்கள் மட்டுமின்றி பொதுமக்கள் மற்றும் வாடிக்கையாளர்கள் மிகுந்த மகிழ்ச்சியை தெரிவித்து வருகின்றனர்.

மத்திய அரசின் இந்தநடவடிக்கை இந்திய மருத்துவ வரலாற்றில்மைல்கல்லாகஇருக்கும் என மருத்துவத்துறையினர் மற்றும் பொதுமக்கள் பாராட்டுதெரிவித்துள்ளனர்.

Summary:

• The Supreme Court condemned high cancer drug prices, prompting the Central Government to cap retail profit margins at 30%.
• The National Pharmaceutical Pricing Authority (NPPA) initiative will reduce drug costs by 70%, saving patients Rs 2,500 crore annually.
• This move covers 110 essential cancer drugs, benefiting poor and middle-class families across India.

Publication Name: Deccan Chronicle
Publication Date: 09/10/2026
Language: English
Edition: Chennai
Page No: 4
CCM: 1259.52

Govt caps trade marginson anti-cancer drugs at 30%

AVINASH PRABHAKAR
NEW DELHI, OCT. 8

The prices of several anti-cancer medicines are likely to fall by up to 70 per cent as the Centre has decided to cap trade margins at 30 per cent of the Maximum Retail Price (MRP) for all non-scheduled anti-cancer drugs, top government sources said here on Thursday.

The move, aimed at curbing excessive mark-ups and reducing the financial burden on cancer patients, will cover all non-scheduled anti-cancer drugs — branded and generic, domestically manufactured and imported, patented and non-pat" ented.

"The proposed TMR is expected to result in significant reductions upto 70 per cent of MRP."

"The intervention would result into expected annual savings of ? 2500 crore and reduction in out-of-pocket expenditure for patients undergoing cancer treatment", told the source.

Sources added further that the intervention will cover all non-scheduled anti-cancer drugs. The list of drugs would be a positive list to be finalised by an expert committee under the Directorate General of Health Services (DGHS).

SC calls for committee on unethical pharma practices

DC CORRESPONDENT
NEW DELHI, OCT. 8

The Supreme Court on Thursday directed the Centre to constitute a committee within two weeks to undertake a holistic and comprehensive examination of issues relating to unethical pharmac eutical marketing practices.

The SC directed that the committee would endeavour to complete the exercise in a time-bound manner and submit its recommendations to the Centre in two months from the date of its first meeting, after duly undertaking the consultative process and considering the material and suggestions placed before it.

The bench passed the order on a plea concerning alleged prevalence of unethical marketing and promotional practices by pharmaceutical companies in their dealings with healthcare professionals.

Summary:

• The Central Government has capped trade margins on non-scheduled anti-cancer drugs at 30% to reduce patient costs by up to 70%.
• The Supreme Court has directed the Centre to form a committee to investigate unethical pharmaceutical marketing practices.
• These measures aim to curb excessive mark-ups and regulate pharmaceutical company dealings with healthcare professionals.

Publication Name: Deccan Chronicle
Publication Date: 09/10/2026
Language: English
Edition: Visakhapatnam
Page No: 5
CCM: 1577.72

SC asks panel to check pharma advt violations

DC CORRESPONDENT
NEW DELHI, OCT. 8

The Supreme Court on Thursday directed the Centre to constitute a committee within two weeks to comprehensively examine unethical pharmaceutical marketing practices.

The court said the committee should endeavour to submit its recommendations to the Centre within two months of its first meeting, after consultations and consideration of the material and suggestions placed before it.

A two-judge bench of Justice Vikram Nath and Justice Sandeep Mehta passed the order on a petition concerning the alleged prevalence of unethical marketing and promotional practices by pharmaceutical companies in their dealings with healthcare professionals.

The petitioners alleged that these practices included direct or indirect monetary benefits, gifts, hospitality, sponsored travel, entertainment and other inducements intended to influence doctors' prescribing practices.

The court noted that the Centre had proposed a three-member committee to examine the issue and recommend an appropriate statutory and regulatory framework to govern the pharma companies.

PERMANENT LIFELINE FOR SMA CARE

DC CORRESPONDENT
NEW DELHI, OCT. 8

The Supreme Court considered creating a permanent corpus fund to finance treatment for people with spinal muscular atrophy (SMA).

Hearing a suo motu case, a three-judge bench comprising CJI Surya Kant, Justice Joymalya Bagchi and Justice V. Mohana said individual charity and ad hoc government grants were insufficient and a regular funding mechanism was needed for life-saving therapies.

CANCER DRUG PRICES LIKELY TO FALL 70%

DC CORRESPONDENT
NEW DELHI, OCT. 8

Prices of several anti-cancer medicines are likely to fall by up to 70 per cent after the Centre decided to cap trade margins at 30 per cent of the maximum retail price (MRP) for all non-scheduled anti-cancer drugs, government sources said on Thursday.

The proposed intervention is aimed at curbing excessive mark-ups and reducing the financial burden on cancer patients.

It will cover all non-scheduled anti-cancer drugs, including branded and generic medicines, and domestically manufactured and imported products, whether patented or non-patented. "The proposed TMR is expected to result in significant reductions up to 70 per cent of MRP.

Summary:

• The Supreme Court directed the Centre to form a committee to curb unethical pharmaceutical marketing practices.
• A three-judge bench is exploring a permanent funding mechanism for spinal muscular atrophy (SMA) treatment.
• The Centre plans to cap trade margins on non-scheduled anti-cancer drugs at 30%, potentially reducing prices by up to 70% for patients.

Publication Name: First India
Publication Date: 09/10/2026
Language: English
Edition: Jaipur
Page No: 5
CCM: 1431.25

CANCER DRUG PRICES CAPPED: GOVT SETS 30% TRADE MARGIN

Centre eyes up to 70% cut in costs

Agencies
New Delhi

The Centre has announced a 30% cap on trade margins for all non-scheduled anti-cancer drugs, a move that could reduce the maximum retail prices (MRPs) of some cancer medicines by up to 70% and save patients an estimated Rs 2,500 crore a year.

The measure will cover branded and generic medicines, as well as domestic and imported, patented and non-patented anti-cancer drugs that fall outside the scheduled price-control framework.

The government said the decision is aimed at curbing excessive mark-ups in the medicine supply chain and making life-saving cancer treatment more affordable, while ensuring that the medicines remain available. The announcement comes against the backdrop of a sharp intervention by the Supreme Court last month over the pricing of cancer medicines, particularly the huge gap between the price at which medicines reach retailers and the MRP charged to patients.

On September 29, a bench of Justices Vikram Nath and Sandeep Mehta questioned the Centre over a cancer drug that was reportedly supplied to retailers for around 2,700 but carried an MRP of Ra 27,000 - a nearly ten-fold difference.

The court questioned why a uniform margin could not be considered for medicines and asked the government to examine the issue. The Bench also raised concerns about corporate hospitals requiring patients to buy medicines from their in-house pharmacies, particularly when treatment is being reimbursed through government schemes.

The court had floated the possibility of a 16% margin framework, similar to the retailer margin used in the price-control mechanism for scheduled formulations. The court, however, had not ordered a nationwide 16% cap. The matter is scheduled to come up again on October 12.

The government's latest move instead extends the existing Trade Margin Rationalisation (TMR) approach to the wider universe of non-scheduled cancer medicines, with the margin fixed at 30%.

There is already precedent for the approach. In 2019, the National Pharmaceutical Pricing Authority (NPPA) capped trade margins at 30% for 42 non-scheduled anti-cancer medicines. The government says that intervention reduced the MRPs of 526 brands by an average of around 50%, generating estimated annual savings of about 984 crore for patients.

The government estimates that the expanded intervention could result in MRP reductions of as much as 70%, depending on the existing trade margins, with total annual savings of around 2,500 crore.



FREEBIES TO DOCTORS : SUPREME COURT ASKS UNION TO FORM PANEL TO RECOMMEND REGULATIONS ON PHARMA MARKETING PRACTICES

The Supreme Court today directed the Union of India to constitute a committee to recommend statutory regulations to curb unethical marketing practices by pharmaceutical companies. "The committee will consider the suggestions and representations and give its recommendations to the Union. The matter is directed to be listed on 29th January for consideration of compliance affidavit by the Union," the Court pronounced. A bench of Justice Vikram Nath and Justice Sandeep Mehta pronounced the order in a petition seeking statutory regulation of pharmaceutical marketing practices to curb unethical interactions between pharmaceutical companies and doctors. The Court had reserved order on the plea after Solicitor General Tushar Mehta informed the Court that the Union government will constitute a three-member committee to examine whether a statutory framework is needed to regulate unethical practices by pharmaceutical companies. The Court had earlier questioned whether the Uniform Code for Pharmaceutical Marketing Practices, 2024 had sufficient enforcement mechanisms. It had also questioned whether the Union government intended to give statutory backing to the Code, noting that the absence of government control could make the purportedly mandatory regime almost voluntary. Solicitor General Tushar Mehta, relying on the Centre's affidavit dated August 17, 2026, said that detailed deliberations have taken place between Department of Pharmaceuticals, Department of Health and Department of Legal Affairs.

Summary:

• The Indian government capped trade margins for non-scheduled anti-cancer drugs at 30% to reduce MRPs by up to 70%.
• The Supreme Court, led by Justice Vikram Nath and Justice Sandeep Mehta, directed the Union of India to form a committee to regulate unethical pharmaceutical marketing practices.
• This initiative aims to make life-saving cancer treatments more affordable.

Publication Name: Lokmat
Publication Date: 09/10/2026
Language: Marathi
Edition: Delhi
Page No: 1
CCM: 934.64

Cancer medicines to become up to 70% cheaper

लोकमत

कॅन्सरवरील औषधी ७०% पर्यंत स्वस्त होणार

मोदी सरकारचा निर्णय: ११० कॅन्सर औषधांवर ३०% ट्रेड मार्जिन मर्यादा

लोकमत न्यूज नेटवर्क

नवी दिल्ली : कॅन्सरसारख्या गंभीर आजाराचा सामना करणाऱ्या रुग्णांसाठी आणि त्यांच्या कुटुंबांसाठी केंद्र सरकारने अत्यंत दिलासादायक निर्णय घेतला आहे. गुरुवारी मोदी सरकारने सर्व विना-नियंत्रित (नॉन-शेड्युल्ड) कॅन्सर औषधांच्या 'ट्रेड मार्जिन'वर (व्यापारी नफा) ३० टक्क्यांची कमाल मर्यादा लागू करण्याची घोषणा केली आहे. या निर्णयामुळे कॅन्सरच्या औषधांच्या कमाल किरकोळ विक्री किमतीत थेट ७० टक्क्यांपर्यंत घसरण होऊ शकते.



महत्त्वाची आकडेवारी

ट्रेड मार्जिन मर्यादा : ३०%
औषधांच्या किमतीत होणारी कपात : ७०% पर्यंत
रुग्णांची वार्षिक बचत : सुमारे २,५०० रुपये कोटी
सवलत मिळणारी एकूण औषधे : ११० औषधे
आदेश लागू होण्याचा कालावधी : १० दिवस

लोकमत विश्लेषण

महागड्या औषधांवरच केंद्र सरकारचे लक्ष का?

औषध निर्माण विभागाच्या अधिकाऱ्यांनी दिलेल्या माहितीनुसार, हा नियम मुख्यत्वे महागड्या कॅन्सर औषधांवरच केंद्रित केला जात आहे. जर स्वस्त औषधांवरही ३० टक्क्यांची मर्यादा लादली, तर कंपन्यांना त्यांचे विपणन आणि वितरण परवडणार नाही आणि त्या बाजारातून गायब होण्याची भीती आहे. त्यामुळे पुरवठा साखळीवर परिणाम न होता रुग्णांना जास्तीत जास्त आर्थिक दिलासा मिळावा, यादृष्टीने हे धोरण आखण्यात आले. भारत सरकारच्या या निर्णयामुळे देशातील लाखो कर्करोग रुग्णांना मोठा आर्थिक दिलासा मिळणार आहे.

New Delhi
Page No. 1 Oct 09, 2026
Powered by: erelego.com

Summary:

The Modi government has capped trade margins on 110 non-scheduled cancer drugs at 30%, potentially reducing retail prices by up to 70%. This initiative, aimed at providing financial relief to lakhs of cancer patients across India, is expected to save patients approximately ₹2,500 crore annually while ensuring supply chain stability.

Publication Name: Malayala Manorama
Publication Date: 09/10/2026
Language: Malayalam
Edition: Delhi
Page No: 7
CCM: 88.57

Trade margin of cancer drugs reduced

കാൻസർ മരുന്നുകളുടെ വ്യാപാരലാഭം കുറച്ചു

ചില്ലറ വിൽപനവില 70% വരെ കുറഞ്ഞേക്കും

ശരണ്യ ഭുവനേന്ദ്രൻ

ന്യൂഡൽഹി● ദേശീയ അവശ്യമരുന്നുവില നിയന്ത്രണപട്ടികയിൽ ഉൾപ്പെടുത്താത്ത (നോൺ ഷെഡ്യൂൾ) എല്ലാ കാൻസർ മരുന്നുകളുടെയും വില കുറയ്ക്കാൻ കേന്ദ്രസർക്കാർ.

ഇത്തരം മരുന്നുകളുടെ വ്യാപാരലാഭം, പരമാവധി ചില്ലറ വിൽപനവിലയുടെ 30 ശതമാനമായി പരിമിതപ്പെടുത്താൻ നാഷനൽ ഫാർമസ്യൂട്ടിക്കൽ പ്രൈസിങ് അതോറിറ്റി (എൻപിപിഎ) ഉത്തരവിട്ടു. ഇതിലൂടെ കാൻസർ മരുന്നുകളുടെ പരമാവധി ചില്ലറ വിൽപനവിലയിൽ (എംആർപി) 70% വരെ കുറഞ്ഞേക്കും.

എൻപിപിഎയുടെ നടപടി രോഗികൾക്കു ഗുണം ചെയ്യില്ലെന്ന് ആരോഗ്യ ആക്ടിവിസ്റ്റ് സംഘടനയായ വർക്കിങ് ഗ്രൂപ്പ് ഓൺ ആക്സസ് ടു ട്രീറ്റ്മെന്റ് ആൻഡ് മെഡിസിൻസ് അറിയിച്ചു. 2019ൽ സമാന നിയന്ത്രണം ഏർപ്പെടുത്തിയിട്ടും കാൻസർ മരുന്നുകളുടെ വില വർധിക്കുകയാണുണ്ടായതെന്നു സംഘടന ചൂണ്ടിക്കാട്ടി.

Summary:

The Central Government, through the National Pharmaceutical Pricing Authority (NPPA), has capped trade margins for non-scheduled cancer drugs at 30% of the MRP. This move, reported by Sharanya Bhuvanendran in New Delhi, aims to reduce retail prices by up to 70%, benefiting patients despite past challenges in price control.

Publication Name: Navodaya Times
Publication Date: 09/10/2026
Language: Hindi
Edition: Delhi
Page No: 1
CCM: 68.47

Prices of 225 cancer drugs will decrease

कैंसर की 225 दवाओं की कीमत होगी कम

नई दिल्ली, 8 अक्तूबर (संतोष सूर्यवंशी/नवोदय टाइम्स): केंद्रीय स्वास्थ्य एवं परिवार कल्याण मंत्री जेपी नड्डा ने कहा है कि सरकार का जोर कैंसर जैसी गंभीर बीमारी के इलाज को अधिक किफायती और मरीज-केंद्रित बनाने पर है। गैर-अनुसूचित एंटी-कैंसर दवाओं पर ट्रेड मार्जिन को 30% तक सीमित करने का फैसला किया गया है जिससे महंगी दवाओं की एमआरपी में 70 प्रतिशत तक कमी आने का अनुमान है। दवाओं की कीमत को सीमित करने का फैसला अगले 8 से 10 दिन में पूर्णतया लागू हो जाएगा।

30% से ज्यादा मुनाफा नहीं वसूल सकेंगे विक्रेता

सरकार की ट्रेड मार्जिन रेशनलाइजेशन व्यवस्था का मकसद इसी मुनाफे को तर्कसंगत सीमा में रखना है, ताकि दवा की कीमत अनावश्यक रूप से न बढ़े। यह सीमा ब्रांडेड और जेनेरिक के साथ घरेलू और आयातित, पेटेंट और गैर-पेटेंट से संबंधित करीब 225 दवाओं पर लागू होगी। सरकार के अनुमान के मुताबिक (शेष पृष्ठ 11 कालम 4 पर)

Summary:

Union Health Minister JP Nadda announced that the Indian government will cap trade margins on 225 anti-cancer drugs at 30%. This initiative aims to make cancer treatment more affordable by potentially reducing MRPs by up to 70%. The policy covers branded, generic, domestic, and imported drugs, with implementation expected within 10 days.

Publication Name: Rashtriya Sagar
Publication Date: 09/10/2026
Language: Hindi
Edition: Delhi
Page No: 1
CCM: 62.33

Expensive cancer drugs could become up to 70 percent cheaper

70 प्रतिशत तक सस्ती हो सकती हैं कैंसर की महंगी दवाएं

नई दिल्ली : देश में कैंसर मरीजों और उनके परिवारों को बड़ी राहत मिलने की उम्मीद है। सरकार कुछ महंगी कैंसर दवाओं पर ट्रेड मार्जिन को 30 प्रतिशत तक सीमित करने की तैयारी कर रही है। इस कदम से चुनिंदा दवाओं की खुदरा कीमत यानी एमआरपी में 70 प्रतिशत तक की कमी आ सकती है। इससे मरीजों के इलाज पर होने वाला जेब से खर्च काफी कम होने की संभावना है। नई व्यवस्था के तहत किन दवाओं को शामिल किया जाएगा, इसकी लिस्ट तैयार करने का काम स्वास्थ्य सेवा महानिदेशालय के महानिदेशक की अध्यक्षता वाली कमेटी कर रही है। सूत्रों के अनुसार, प्रस्तावित व्यवस्था करीब 10 दिनों के अंदर लागू हो सकती है। डिपार्टमेंट ऑफ फार्मास्यूटिकल्स के सूत्रों के मुताबिक, सरकार ऐसी कैंसर दवाओं की पहचान कर रही है जिनकी कीमत काफी अधिक है और जिनका इस्तेमाल मरीजों के इलाज में नियमित रूप से होता है। प्रस्तावित व्यवस्था के तहत इन दवाओं पर डिस्ट्रीब्यूटर की लागत के ऊपर ट्रेड मार्जिन को 30 प्रतिशत तक सीमित किया जाएगा। वर्ष 2019 में एक पायलट प्रोजेक्ट के तहत 42 कैंसर दवाओं के ट्रेड मार्जिन को सीमित किया गया था।

Summary:

• The Indian government plans to cap trade margins on expensive cancer drugs at 30%, potentially reducing MRP by up to 70%.
• A committee under the Director General of Health Services is finalizing the list of drugs.
• This initiative aims to significantly lower out-of-pocket treatment costs for cancer patients across the country.

Publication Name: The Hans India
Publication Date: 09/10/2026
Language: English
Edition: Hyderabad
Page No: 7
CCM: 142.21

GOVT CAPS TRADE MARGINS AT 30%

CANCER DRUGS PRICES LIKELY TO FALL BY 70%

NEW DELHI

CANCER patients could soon see a sharp drop in the price of some of the country's costliest medicines, with the government moving to cap trade margins at 30% over the cost to distributors.

The move will cover expensive cancer drugs, including some patented medicines, and could bring down their retail prices (MRPs) by as much as 70%, Department of Pharmaceuticals sources said.

The decision comes as the government seeks to rein in steep mark-ups in the cancer drug market. It builds on a 2019 pilot under which trade margins on 42 cancer medicines were capped. The latest move is aimed specifically at high-priced drugs, where even a relatively large margin translates into a substantial increase in the price paid by patients. For cancer patients and their families, the move could directly lower the amount they pay for some of the most expensive medicines. A cut in MRP of up to 70% could translate into significant savings, particularly for patients requiring prolonged treatment with high-cost drugs. The impact, however, will depend on which medicines make the final list and how much of the existing trade margin is actually passed on to patients.

A committee headed by the Director General of Health Services is now drawing up the list of medicines that will come under the new regime. The measure is expected to take effect within 10 days. Drugs being considered will have to be approved for cancer treatment in India and be in frequent use, apart from meeting the key criterion of being expensive.

Summary:

• The Indian government, through the Department of Pharmaceuticals, is capping trade margins on expensive cancer drugs at 30%.
• A committee led by the Director General of Health Services is identifying medicines for this price-reduction initiative.
• This policy aims to significantly lower retail prices for cancer patients in India by up to 70%.

ONLINE MEDIA

Downloaded from
SAMVAD 2.0

Sr. No.	Headline	Website	Sentiment	Date	Time	Source
1	Chemist body welcomes govt move to rationalise cancer drug prices in country	ANI	POSITIVE	09/10/2026	2:53 AM	Link
2	Cancer drugs prices could fall by 70% as government plans profit margin caps	Indian Express	POSITIVE	09/10/2026	5:38 AM	Link
3	Cancer drug costs to come down by up to 70% as govt caps trade margin at 30%	India Today	POSITIVE	09/10/2026	5:36 AM	Link
4	Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources	NDTV	POSITIVE	09/10/2026	5:40 AM	Link
5	Anti-cancer medicines will become cheaper	Punjabi Tribune Online	POSITIVE	09/10/2026	2:32 AM	Link
6	Cancer drug prices to drop as govt caps trade margin at 30pc	Rediff	POSITIVE	09/10/2026	5:33 AM	Link
7	Centre to cap trade margins at 30% for non-scheduled anti-cancer drugs	The Tribune	POSITIVE	09/10/2026	1:07 AM	Link
8	Government plans 30% margin cap on cancer drugs — 110 medicines may see major price cuts	ZeeBiz	POSITIVE	08/10/2026	7:16 PM	Link
9	Big relief for cancer patients soon; 70% reduction in cancer drug prices likely	TV9 Kannada	POSITIVE	08/10/2026	11:09 PM	Link
10	Breaking News: Supreme Court strict on unethical marketing practices of pharma companies, orders Centre to form a committee	TV9 Gujarati	POSITIVE	08/10/2026	11:58 AM	Link
11	Prices of cancer drugs to decrease… Government's big decision, how much trade margin fixed?	TV9 Bharatvarsh	POSITIVE	08/10/2026	9:09 PM	Link
12	Centre to cap trade margins at 30% for non-scheduled cancer drugs	The Tribune	POSITIVE	08/10/2026	8:49 PM	Link
13	Supreme Court orders Centre to form panel to regulate unethical pharma marketing	The Hindu	POSITIVE	08/10/2026	1:19 PM	Link
14	Cancer drug prices to drop sharply; Central Government limits trade margin to 30 percent	Suprabhaatham	POSITIVE	08/10/2026	8:21 PM	Link
15	India News: Pharma companies are no longer safe... Supreme Court takes a tough stance on doctors receiving expensive gifts for prescribing costly medicines	Sandesh	POSITIVE	08/10/2026	2:00 PM	Link

Downloaded from
SAMVAD 2.0

Sr. No.	Headline	Website	Sentiment	Date	Time	Source
16	Government's big decision on non-scheduled cancer drugs, now shopkeepers will not be able to take more than 30% profit	Sandesh	POSITIVE	08/10/2026	6:53 PM	Link
17	Anti-cancer drug prices may fall by up to 70% as govt plans trade margin cap	Prameya	POSITIVE	08/10/2026	12:00 AM	Link
18	'Expensive gifts to doctors for prescribing expensive medicines', SC prepares to tighten grip on pharma companies, directs formation of committee	NDTV India	POSITIVE	08/10/2026	11:48 AM	Link
19	Supreme Court asks Centre to form committee to examine pharma firms offering expensive gifts, incentives to doctors	Money Control	POSITIVE	08/10/2026	11:29 AM	Link
20	India urea offers fall in sign of easing global fertilizer costs	Money Control	POSITIVE	08/10/2026	6:35 PM	Link
21	Cancer drug prices to decrease significantly: Central Government orders to cap trade margin at 30 percent	Maalai Malar	POSITIVE	08/10/2026	6:32 PM	Link
22	Government takes decision after Supreme Court's warning; Cancer patients and families get major relief	Lokmat	POSITIVE	08/10/2026	8:11 PM	Link
23	Big relief for cancer patients! Expensive medicines could become up to 70% cheaper, government has made a big plan	Jansatta	POSITIVE	08/10/2026	7:23 PM	Link
24	SC directs Centre to form panel on curbing unethical pharma marketing practices	India Today	POSITIVE	08/10/2026	12:01 PM	Link
25	Prices of 110 anti-cancer drugs to fall sharply	Financial Express	POSITIVE	08/10/2026	8:07 PM	Link
26	Big relief in cancer drugs, can government decision reduce prices significantly?	Ei Samay	POSITIVE	08/10/2026	10:47 PM	Link
27	Supreme Court asks Centre to frame statutory rules for pharma marketing	Business Standard	POSITIVE	08/10/2026	10:24 PM	Link
28	Cancer drug prices to drop by up to 70%; Central Government takes crucial decision; action follows Supreme Court directive	Asianet News	POSITIVE	08/10/2026	7:09 PM	Link
29	Anti-cancer drug prices may fall by up to 70% as govt plans trade margin cap	ANI	POSITIVE	08/10/2026	7:44 PM	Link
30	Government's big decision on cancer drugs, trade margin limited to 30%	ABP Asmita	POSITIVE	08/10/2026	6:57 PM	Link

Website:
ANI

Published Date:
09/10/2026

Time:
2:53 AM

Language:
English

Source:
Link

Summary:

The All India Organisation of Chemists & Druggists (AIOCD), led by President JS Shinde and General Secretary Rajiv Singhal, welcomed the Indian government's decision to cap trade margins on non-scheduled anti-cancer drugs at 30%. This policy aims to reduce high-cost medicine prices, potentially saving patients Rs 2,500 crore annually and improving accessibility to life-saving treatments across India.

Website:
Indian Express

Published Date:
09/10/2026

Time:
5:38 AM

Language:
English

Source:
Link

Summary:

The Indian government, through the Department of Pharmaceuticals and National Pharmaceutical Pricing Authority, plans to cap trade margins at 30% for 110 cancer drugs to reduce patient costs. While the Supreme Court criticized high markups, experts like KM Gopakumar warn that patented drugs may remain expensive, suggesting the need for stronger patent law interventions.

Website:
India Today

Published Date:
09/10/2026

Time:
5:36 AM

Language:
English

Source:
Link

Summary:

The Indian government has capped trade margins at 30% for non-scheduled anti-cancer drugs to reduce costs by up to 70%. Following Supreme Court scrutiny regarding high mark-ups, the National Pharmaceutical Pricing Authority (NPPA) aims to save patients Rs 2,500 crore annually. This measure targets excessive supply chain mark-ups while ensuring the availability of life-saving cancer treatments.

Website:
NDTV

Published Date:
09/10/2026

Time:
5:40 AM

Language:
English

Source:
Link

Summary:

• The Department of Pharmaceuticals, under the Indian Government, has capped trade margins for non-scheduled anti-cancer drugs at 30% of the MRP.
• This move follows Supreme Court scrutiny regarding excessive price gaps between retailer costs and MRP.
• The initiative aims to reduce financial burdens on cancer patients, with estimated annual savings of Rs 2,500 crore.

Website:
Punjabi Tribune Online

Published Date:
09/10/2026

Time:
2:32 AM

Language:
Punjabi

Source:
Link

Summary:

The Central Government is capping trade margins on 110 anti-cancer drugs at 30% to make them affordable, saving patients ¹2,500 crore annually. Additionally, the Supreme Court, led by Justice Vikram Nath and Justice Sandeep Mehta, has ordered the government to form a committee to investigate unethical marketing practices by pharmaceutical companies.

Website:
Rediff

Published Date:
09/10/2026

Time:
5:33 AM

Language:
English

Source:
Link

Summary:

The Indian government is capping trade margins on 110 anti-cancer drugs at 30% to improve affordability. This initiative, overseen by the health department, aims to save patients Rs 2,500 crore annually. The Supreme Court, including Justice Vikram Nath and Justice Sandeep Mehta, previously highlighted concerns regarding inflated drug pricing, prompting this regulatory action.

Website:
The Tribune

Published Date:
09/10/2026

Time:
1:07 AM

Language:
English

Source:
Link

Summary:

• The Central Government of India, through the National Pharmaceutical Pricing Authority (NPPA), will cap trade margins at 30% for 110 non-scheduled anti-cancer drugs.
• This initiative aims to reduce out-of-pocket expenditure for cancer patients by an estimated Rs 2,500 crore annually.
• The move addresses excessive profiteering and market distortions in the pharmaceutical sector across India.

Website:
ZeeBiz

Published Date:
08/10/2026

Time:
7:16 PM

Language:
English

Source:
Link

Summary:

The Department of Pharmaceuticals (DoP) and the National Pharmaceutical Pricing Authority (NPPA) are planning a 30% trade margin cap on 110 non-scheduled cancer drugs. This government initiative aims to reduce MRPs by up to 70%, potentially saving patients Rs 2,500 crore annually by curbing excessive distributor and retailer margins.

Website:
TV9 Kannada

Published Date:
08/10/2026

Time:
11:09 PM

Language:
Kannada

Source:
Link

Summary:

The Central Government is set to cap trade margins on cancer drugs at 30%, potentially reducing retail prices by 70%. This initiative aims to save patients Rs 2,500 crore annually. The Ministry of Health and Family Welfare is finalizing this policy to ensure life-saving medicines remain affordable and accessible across India.

Website:
TV9 Gujarati

Published Date:
08/10/2026

Time:
11:58 AM

Language:
Gujarati

Source:
Link

Summary:

The Supreme Court, led by Justice Vikram Nath and Justice Sandeep Mehta, ordered the Central Government to form a committee to curb unethical marketing and freebies by pharmaceutical companies. The government confirmed the Uniform Code for Pharmaceutical Marketing Practices, 2024 remains active until the committee submits its recommendations to regulate the industry.

Website:
TV9 Bharatvarsh

Published Date:
08/10/2026

Time:
9:09 PM

Language:
Hindi

Source:
Link

Summary:

• The Central Government of India has capped trade margins on non-scheduled anti-cancer drugs at 30% to make treatment affordable.
• This initiative aims to reduce patient out-of-pocket expenses by up to 70% for certain drugs.
• The Ministry of Health and Family Welfare regulates these prices under the Drugs (Prices Control) Order, 2013.

Website:
The Tribune

Published Date:
08/10/2026

Time:
8:49 PM

Language:
English

Source:
Link

Summary:

The Central Government of India, through the National Pharmaceutical Pricing Authority (NPPA), is capping trade margins at 30% for non-scheduled anti-cancer drugs. This initiative aims to reduce the financial burden on cancer patients by lowering MRPs by up to 70%, potentially saving Rs 2,500 crore annually and curbing excessive profiteering in the pharmaceutical market.

Website:
The Hindu

Published Date:
08/10/2026

Time:
1:19 PM

Language:
English

Source:
Link

Summary:

The Supreme Court bench of Justices Vikram Nath and Sandeep Mehta directed the Union government to form an expert committee. This panel will evaluate implementing a legally enforceable framework to regulate unethical marketing practices by pharmaceutical companies in India.

Website:
Suprabhaatham

Published Date:
08/10/2026

Time:
8:21 PM

Language:
Malayalam

Source:
Link

Summary:

• The Central Government, following a Supreme Court directive, capped trade margins on non-listed cancer drugs at 30%.
• This move aims to reduce drug prices by up to 70%, benefiting patients with annual savings of 2,500 crore rupees.
• Over 110 anti-cancer drugs will now be more affordable, curbing exploitation in cancer treatment across India.

Website:
Sandesh

Published Date:
08/10/2026

Time:
2:00 PM

Language:
Gujarati

Source:
Link

Summary:

• The Supreme Court, led by Justice Vikram Nath and Justice Sandeep Mehta, ordered the Central Government to form a committee to probe unethical marketing by pharma companies.
• The Federation of Medical and Sales Representatives Association of India (FMRAI) filed a petition against doctors receiving expensive gifts for prescribing costly drugs.
• The committee will evaluate strengthening the UCPMP 2024.

Website:
Sandesh

Published Date:
08/10/2026

Time:
6:53 PM

Language:
Gujarati

Source:
Link

Summary:

The Central Government has capped the profit margin on non-scheduled cancer drugs at 30% to reduce treatment costs. This initiative by the government is expected to save patients approximately 2,500 crores annually. The National Pharmaceutical Pricing Authority regulates these essential medicines, aiming to make life-saving cancer treatments more affordable for patients across India.

Website:
Prameya

Published Date:
08/10/2026

Time:
12:00 AM

Language:
English

Source:
Link

Summary:

The Indian Government is planning to cap trade margins at 30% for non-scheduled anti-cancer drugs. This initiative, overseen by the Department of Pharmaceuticals and the National Pharmaceutical Pricing Authority, aims to improve affordability for cancer patients, potentially reducing drug prices by up to 70% and saving Rs 2,500 crore annually.

Website:
NDTV India

Published Date:
08/10/2026

Time:
11:48 AM

Language:
Hindi

Source:
Link

Summary:

• The Supreme Court, led by Justice Vikram Nath and Justice Sandeep Mehta, ordered the Central Government to form a committee to curb unethical marketing practices by pharma companies.
• The FMRAI petition alleges that pharma companies offer expensive gifts and foreign trips to doctors to influence prescriptions.
• The committee will evaluate the need for a new statutory framework.

Website:
Money Control

Published Date:
08/10/2026

Time:
11:29 AM

Language:
English

Source:
Link

Summary:

• The Supreme Court, led by Justices Vikram Nath and Sandeep Mehta, ordered the Centre to form a committee to regulate unethical pharmaceutical marketing.
• The Federation of Medical and Sales Representatives Association filed a 2021 petition against pharma companies offering incentives to doctors.
• The Centre must submit a report on a statutory framework by January 29.

Website:
Money Control

Published Date:
08/10/2026

Time:
6:35 PM

Language:
English

Source:
Link

Summary:

Indian Potash Ltd. received urea import offers nearly 10% lower than August prices. This decline in global fertilizer costs, monitored by the Indian government, eases pressure on the national fertilizer subsidy bill. These lower prices benefit Indian farmers preparing for the winter planting season for crops like wheat, rapeseed, and chickpeas.

Website:
Maalai Malar

Published Date:
08/10/2026

Time:
6:32 PM

Language:
Tamil

Source:
Link

Summary:

• The Central Government, under the Ministry of Chemicals and Fertilizers, capped trade margins for 110 cancer drugs at 30%, potentially reducing prices by 70%.
• This initiative aims to save patients Rs 2,500 crore annually, following Supreme Court concerns over excessive profiteering.
• The policy ensures affordable access to life-saving treatments for poor and middle-class families across India.

Website:
Lokmat

Published Date:
08/10/2026

Time:
8:11 PM

Language:
Marathi

Source:
Link

Summary:

• The Central Government capped trade margins on cancer drugs at 30% to make treatment affordable.
• The Supreme Court intervened after noting excessive retail markups on life-saving medicines.
• This initiative aims to save Indian cancer patients approximately 2,500 crore rupees annually by reducing drug costs by up to 70%.

Website:
Jansatta

Published Date:
08/10/2026

Time:
7:23 PM

Language:
Hindi

Source:
Link

Summary:

The Department of Pharmaceuticals, under the Indian Government, is planning to cap trade margins on expensive cancer drugs at 30%, potentially reducing MRP by 70%. A committee led by the Director General of Health Services (DGHS) is finalizing the list of drugs. This initiative aims to significantly lower the financial burden on cancer patients across India.

Website:
India Today

Published Date:
08/10/2026

Time:
12:01 PM

Language:
English

Source:
Link

Summary:

The Supreme Court, led by Justices Vikram Nath and Sandeep Mehta, directed the Union of India to form a three-member committee. This panel will evaluate representations to regulate unethical marketing by pharmaceutical companies. The government must submit a compliance affidavit by January 29, while the Uniform Code for Pharmaceutical Marketing Practices, 2024, remains in effect.

Website:
Financial Express

Published Date:
08/10/2026

Time:
8:07 PM

Language:
English

Source:
Link

Summary:

The Department of Pharmaceuticals (DoP) is capping trade margins at 30% for 110 non-scheduled anti-cancer drugs. This government initiative, prompted by Supreme Court scrutiny over high mark-ups, aims to reduce MRPs by up to 70%. The move is expected to save patients Rs 2,500 crore annually by regulating prices of generics, patented, and imported medicines.

Website:
Ei Samay

Published Date:
08/10/2026

Time:
10:47 PM

Language:
Bengali

Source:
Link

Summary:

The Central Government, through the National Pharmaceutical Pricing Authority (NPPA), has decided to cap trade margins for non-scheduled cancer drugs at 30%. This move aims to significantly reduce the MRP of essential cancer medications, providing major relief to patients. The Supreme Court had previously urged the government to address the high costs and margins of these life-saving drugs.

Website:
Business Standard

Published Date:
08/10/2026

Time:
10:24 PM

Language:
English

Source:
Link

Summary:

• The Supreme Court directed the Centre to form a committee to regulate pharma marketing practices.
• The Federation of Medical and Sales Representatives' Associations of India filed the petition to curb unethical incentives to doctors.
• Solicitor General Tushar Mehta stated the government is evaluating the need for a statutory framework to address these industry practices.

Website:
Asianet News

Published Date:
08/10/2026

Time:
7:09 PM

Language:
Malayalam

Source:
Link

Summary:

• The Central Government, following a Supreme Court directive, capped trade margins on cancer drugs at 30%.
• This initiative will reduce prices by up to 70%, benefiting patients with annual savings of Rs 2,500 crore.
• The National Pharmaceutical Pricing Authority will oversee this regulation, impacting over 110 anti-cancer drugs to ensure affordability for citizens.

Website:
ANI

Published Date:
08/10/2026

Time:
7:44 PM

Language:
English

Source:
Link

Summary:

• The Indian Government plans to cap trade margins on non-scheduled anti-cancer drugs at 30% of MRP.
• This initiative, overseen by the Department of Pharmaceuticals and NPPA, aims to reduce drug costs by up to 70%.
• The move seeks to improve healthcare affordability for cancer patients, potentially saving Rs 2,500 crore annually.

Website:
ABP Asmita

Published Date:
08/10/2026

Time:
6:57 PM

Language:
Gujarati

Source:
Link

Summary:

The Central Government has capped trade margins on all non-scheduled anti-cancer drugs at 30% to reduce treatment costs. The National Pharmaceutical Pricing Authority (NPPA) initiative aims to lower MRPs by up to 70%, potentially saving patients ¹2,500 crore annually. This policy covers both branded and generic, as well as imported and domestic, anti-cancer medications.